

A black and white photograph of the Golden Gate Bridge in San Francisco, with the city skyline visible in the background. The bridge's towers and suspension cables are prominent, framing the city. The text is overlaid on the top half of the image.

BIOTECH SHOWCASE™ 2015

INVESTOR SUMMARY PROFILES OF PRESENTING COMPANIES

January 12-14, 2015 • San Francisco, CA
Parc 55 Wyndham San Francisco – Union Square

CO-PRODUCERS

**DEMY
COLTON**

**EBD
GROUP**

January 12, 2015

Welcome to the Seventh Annual Biotech Showcase!

We are excited that you are here with us in San Francisco as we begin 2015 at the leading event where innovative private and public life sciences companies present to the investor community and build their corporate profiles to attract funding and strategic partners.

In the wake of a year where the industry surpassed virtually every financial benchmark imaginable, we are pleased to welcome over 1,900 delegates and 230 presenting companies – including our largest class of public companies to date. This critical mass of talent and opportunity makes Biotech Showcase the leading event where you can meet high-growth, high-caliber and innovative emerging life sciences companies.

*In addition to the presenting companies, Biotech Showcase features a top-notch program of plenary sessions and business workshops covering public and private financial markets, therapeutic advances in areas such as cancer immunotherapy and type 1 diabetes, and how to manage the regulatory thicket of the FDA, SEC, CMS and other agencies. We will also present the third annual edition of *The Life Sciences Report 2015 Small-Cap Watchlist*.*

We wish all of you a very productive conference.

Sincerely,

*Sara Jane Demy
Founder & CEO
Demy-Colton Life Science Advisors*

*Anna Chrisman
Group Managing Director
EBD Group*

NOTES

Abzena plc (LSE AIM: ABZA)

Abzena provides a suite of services and technologies that enable the development of better biopharmaceuticals. Its service operations provide a growing revenue stream, and it sees the potential for additional revenue through royalty-bearing licenses for the application of its technology by partners.

Location: Cambridge, United Kingdom

Year Established: 2001

Website: www.abzena.com

Therapeutic Focus: Immunology, Antibody Humanization

Development Status: NA

Corporate Partners: NA

Funds Raised: About \$33 M raised in July 2014 in conjunction with an IPO

Presenter: Donna Hackett, VP, IP, Legal and Commercial Affairs

ACEA Biosciences, Inc.

ACEA Biosciences is a development-stage biotechnology company with an emphasis on oncology and inflammation. The company's pipeline includes four preclinical and clinical-stage assets.

Location: San Diego, California United States

Year Established: 2002

Website: www.aceabio.com

Therapeutic Focus: Oncology, Inflammation, Drug Discovery Platform

Development Status: Phase 2a, Phase 1, late Preclinical (Phase 1 early 2015), and Preclinical

Corporate Partners: NA

Funds Raised: Raised approx. \$12 M 2003-07. Self-supported since 2008 by product revenue, contracts, government grants

Presenter: Xiao Xu, MD, PhD

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)

Actinium is developing targeted payload immunotherapeutics for the treatment of advanced cancers. Its targeted radiotherapy is based on its delivery platform for the therapeutic use of alpha-emitting actinium-225 and bismuth-213 and certain beta-emitting radiopharmaceuticals in conjunction with monoclonal antibodies.

Location: New York, New York United States

Year Established: 2000

Website: www.actiniumpharma.com

Therapeutic Focus: Oncology, Acute Myeloid Leukemia, Iomab-B, Actimab-A

Development Status: Phase 1/2, Phase 3

Corporate Partners: NA

Funds Raised: The company recently closed a secondary offering in conjunction with Cannacord Genuity

Presenter: Kaushik J. Dave, PhD, MBA, President & CEO

Adaptimmune Limited

Adaptimmune is a clinical-stage cell therapy company targeting cancer. It has multiple clinical trials of its engineered TCR T-cell under way in the US.

Location: Oxford / Philadelphia, United Kingdom / USA

Year Established: 2008

Website: www.adaptimmune.com

Therapeutic Focus: T-Cell Therapy in Cancer

Development Status: Phase 2

Corporate Partners: GSK

Funds Raised: \$104 M in September 2014

Presenter: James Noble, MA FCA, CEO

Admedus (ASX: AHZ)

Admedus invests in and develops next-generation technologies. Its lead regenerative tissue product, CardioCel™, is on the market in the US and Europe. The company has diversified assets that range from those in R&D to marketed products.

Location: Australia and Minneapolis, Minnesota United States

Year Established: 2004 / US Entity 2013

Website: www.admedus.com

Therapeutic Focus: Therapeutic Vaccines Targeting Infectious Diseases, Oncology

Development Status: Phase 1 to market

Corporate Partners: NA

Funds Raised: \$45+ M with \$29 M raised in 2013

Presenter: Dr. Julian Chick, COO

Advanced Inhalation Therapies

This Phase 2 biopharmaceutical company uses a nitric oxide formulation to treat various respiratory diseases. It has completed a successful Phase 2a trial for RSV and cystic fibrosis and expects to finish a Phase 2b this winter and prepare for Phase 3 trials in October 2015.

Location: Rehovot, Israel

Year Established: 2011

Website: ait-pharm.com

Therapeutic Focus: Respiratory Diseases

Development Status: Phase 2b for RSV and Cystic Fibrosis

Corporate Partners: Clalit Health care, the second largest HMO in the world

Funds Raised: \$3.5 M

Presenter: Amir Avniel, President & CEO

Aeterna Zentaris Inc. (NASDAQ: AEZS)

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing treatments in oncology and endocrinology. Its lead clinical program is a Phase 3 trial in endometrial cancer. The company has also started a commercial program with the co-promotion of an estrogen replacement therapy in some US areas.

Location: Quebec, Quebec Canada

Year Established: 1991

Website: www.aezsinc.com

Therapeutic Focus: Oncology, Endocrinology, Women's Health

Development Status: Phase 3 in advanced, recurrent or metastatic endometrial cancer

Corporate Partners: Sinopharm; Spectrum Pharmaceuticals (outside of Japan)

Funds Raised: Approx. \$24.4 M in 2014

Presenter: David A. Dodd, Chairman & CEO

Aethlon Medical, Inc. (OTC: AEMD)

Aethlon Medical is a clinical-stage company with a first-in-class device that selectively targets the rapid elimination of circulating viruses including Ebola, Hep C and HIV. It also targets tumor-secretive exosomes that promote cancer progression.

Location: San Diego, California United States

Year Established: 1999

Website: www.aethlonmedical.com

Therapeutic Focus: Ebola Virus, Hepatitis-C Virus, HIV, Sepsis

Development Status: Clinical-stage products

Corporate Partners: Government contracts with the US Department of Defense

Funds Raised: \$5+ M in 2014; \$30+ M since inception.

Presenter: Jim Joyce, Chairman & CEO

AgeneBio, Inc.

AgeneBio is a clinical-stage pharmaceutical company with a Phase 3-ready product that may slow the progression or delay the onset of Alzheimer's dementia. It also has a small molecule program targeting unmet needs in CNS diseases including aMCI, autism and schizophrenia.

Location: Baltimore, Maryland United States

Year Established: 2008

Website: www.agenebio.com

Therapeutic Focus: Alzheimer's, Dementia; Autism, Schizophrenia, MCI

Development Status: Phase 3-ready, Late Discovery Stage Program, IND 4Q15/1Q16

Corporate Partners: NA

Funds Raised: ~\$15 M Oct. 31, 2014; \$5 M across 3 angel rounds, \$2.2 M UO1 grant, non-dilutive, \$7.5 M Series A

Presenter: Jerry McLaughlin, President & CEO

Amarantus Bioscience (OTCQB: AMBS)

Amarantus Bioscience is a clinical-stage biotechnology company that discovers and develops treatments and diagnostics for neurodegenerative diseases. The company has a Phase 2b ready asset for Parkinson's Levodopa Induced Dyskinesia and has an exclusive license to the Lymphocyte Proliferation test.

Location: San Francisco, California United States

Year Established: 2008

Website: www.amarantus.com

Therapeutic Focus: Neurology, Psychiatry, Ophthalmology, Alzheimer's disease, Parkinson's Disease, Retinitis Pigmentosa, Wolfram Syndrome, Diabetes, Traumatic Brain Injury, Ischemia and Intractable Severe Burns

Development Status: Clinical stage

Corporate Partners: ICON Labs; Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd.; Janssen Labs @QB3

Funds Raised: NA

Presenter: Gerald E. Commissiong, President & CEO

Anavex Life Sciences (OTC: AVXL)

Anavex is a clinical-stage biopharmaceutical company focused on the discovery of drug candidates to treat Alzheimer's disease, other CNS diseases and various types of cancer.

Location: New York, New York United States

Year Established: 2006

Website: www.anavex.com

Therapeutic Focus: Alzheimer's, Cancer Therapeutics, CNS, incl. ALS, Parkinson's Disease, Depression, Epilepsy

Development Status: Lead product for Alzheimer's is in Phase 2 clinical trial

Corporate Partners: NA

Funds Raised: More than \$28 M raised and \$10 M in 2014

Presenter: Christopher U. Missling, PhD, CEO

Anergis SA

Anergis is a clinical-stage company developing proprietary allergy vaccines that would require only two months of treatment. The clinical efficacy and disease-modifying potential of its lead candidate has been confirmed over two natural birch pollen seasons in 240 patients.

Location: Epalinges-Lausanne, Switzerland

Year Established: 2001

Website: www.anergis.ch

Therapeutic Focus: Respiratory, Allergic Rhinitis

Development Status: AllerT - Phase 2b

Corporate Partners: NA

Funds Raised: \$45 M with \$2 M seed, \$20 M round A in 2011, \$22 M round B, 2014

Presenter: Vincent Charlon, CEO

Antisense Therapeutics Ltd. (ASX: ANP)

Antisense Therapeutics is developing an advanced-stage pipeline of second-generation antisense drugs. Its lead compounds are in Phase 2 clinical development with near-term milestones acting on validated targets in acromegaly and multiple sclerosis. It has a partnership and worldwide licensing agreement with Isis Pharmaceuticals.

Location: Toorak, Victoria Australia

Year Established: 2000

Website: www.antisense.com.au

Therapeutic Focus: Second-Generation Antisense Drugs for Acromegaly, Multiple Sclerosis, Prostate Cancer, Asthma

Development Status: Two Phase 2 programs, several preclinical

Corporate Partners: Isis Pharmaceuticals (Nasdaq: ISIS)

Funds Raised: NA

Presenter: Mark Diamond, Managing Director & CEO

Aperiomics, Inc.

Aperiomics is a service company that conducts pathogen diagnostics through a novel combination of genomics and informatics. It capitalizes on high-throughput next-generation sequencing technologies and advanced Bayesian statistics to provide more accurate results than other molecular based approaches and faster and more accurate results than culture-based methods.

Location: Ashburn, Virginia United States

Year Established: 2013

Website: www.aperiomics.com

Therapeutic Focus: Infectious Disease, Molecular Diagnostics, Next-generation Sequencing

Development Status: Marketed

Corporate Partners: PepperPath, LLC

Funds Raised: \$525K seed capital through founders and gov. grants since inception

Presenter: Crystal R. Icenhour, PhD, CEO

Apogenix GmbH

Apogenix develops protein therapeutics for the treatment of diseases such as cancer by targeting pathways involved in growth, migration and apoptosis of diseased cells. Its most advanced product has a successfully controlled completed Phase 2 proof-of-concept study for the treatment of brain tumors.

Location: Heidelberg, Germany

Year Established: 2005

Website: www.apogenix.com

Therapeutic Focus: Oncology

Development Status: Preclinical, Phase 1, Phase 2

Corporate Partners: AbbVie

Funds Raised: More than \$70 M in four rounds plus \$10 M public grants

Presenter: Thomas Hoeger, PhD, CEO & CFO

Apricus Biosciences, Inc. (NASDAQ: APRI)

This company's lead product is approved for the treatment of erectile dysfunction in Europe and Canada and will be commercialized by its marketing partners. Its second-generation of the device is under development. It has also recently initiated a Phase 2a trial for a product for the treatment of Raynaud's phenomenon.

Location: San Diego, California United States

Year Established: 1987

Website: www.apricusbio.com

Therapeutic Focus: Urology, Rheumatology

Development Status: Marketed, Phase 2a and Phase 2b

Corporate Partners: Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle

Funds Raised: NA

Presenter: Rich Pascoe, CEO

Aptose Biosciences Inc. (NASDAQ: APTO)

This clinical-stage biotechnology company has a lead program that has completed a Phase 1 study in patients with solid tumors. It recently received IND allowance from the FDA to initiate a Phase 1b study in patients with relapsed refractory blood cancers including AML, high-risk MDA, lymphomas and multiple myeloma.

Location: Toronto, Ontario Canada

Year Established: 2007

Website: www.aptose.com

Therapeutic Focus: Hematology, Oncology

Development Status: Phase 1b

Corporate Partners: NA

Funds Raised: CAD \$46 M since Nov. 2013

Presenter: Dr. William G. Rice, Chairman, President & CEO

Aradigm Corporation (NASDAQ: ARDM)

Aradigm is a clinical-stage company targeting respiratory diseases and infections. Its lead program is in Phase 3 trials in bronchiectasis patients. The company may pursue additional indications for its lead candidate including cystic fibrosis, non-TB mycobacterial lung infections and biodefense applications.

Location: Hayward, California United States

Year Established: 1991

Website: www.aradigm.com

Therapeutic Focus: Respiratory Diseases, Respiratory Infections

Development Status: Phase 3 clinical trials Lipoquin and Pulmaquin; inhaled nicotine Phase 2 ready; respiratory diagnostics Phase 1/2a; inhaled insulin Phase 3-ready

Corporate Partners: Grifols, Inc.

Funds Raised: Current funding from the partner Grifols, investors and NIH

Presenter: Igor Gonda, PhD, President & CEO

Arch Therapeutics, Inc. (OTCBB: ARTH)

Arch is a pre-clinical medical device company with an innovative approach to the rapid cessation of bleeding and control of fluid leakage during surgery and trauma care. The underlying technology supports a platform of smart materials that address a specialized field that it calls “stasis and barrier applications.”

Location: Wellesley, Massachusetts United States

Year Established: 2006

Website: www.archtherapeutics.com

Therapeutic Focus: Medical device, Surgical Hemostatic Device

Development Status: Preclinical development. First product, AC5 Surgical Hemostatic Device

Corporate Partners: NA

Funds Raised: approx. \$10 M

Presenter: Terrence W. Norchi, MD, President & CEO

Arcturus Therapeutics, Inc.

Arcturus is a pre-clinical company focused on the application of RNA technologies for the treatment of disease and improved quality of life.

Location: San Diego, California United States

Year Established: 2013

Website: www.ArcturusRx.com

Therapeutic Focus: Rare Disease, TTR

Development Status: Preclinical

Corporate Partners: Tekmira, Arrowhead, Marina

Funds Raised: \$7.3 M

Presenter: Joseph E. Payne, President & CEO

arGEN-X NV (EURONEXT: ARGX)

arGEN-X is a clinical-stage biopharmaceutical company that creates and develops differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases. It has generated a pipeline of differentiated antibody candidates through its discovery platform.

Location: Breda, The Netherlands

Year Established: 2008

Website: www.argen-x.com

Therapeutic Focus: Oncology, Severe Autoimmunity

Development Status: ARGX-110: Phase 1b; ARGX-111: Phase 1; ARGX-113: Preclinical

Corporate Partners: Shire, Bayer, Boehringer Ingelheim, RuiYi, BioWa

Funds Raised: €46.0 M venture capital funding; €7.0 M non-dilutive grants

Presenter: Tim Van Hauwermeiren, CEO

Argos Therapeutics, Inc. (NASDAQ: ARGX)

Argos Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing personalized immunotherapies for the treatment of cancer and infectious disease. Its lead candidate is in Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma.

Location: Durham, North Carolina United States

Year Established: NA

Website: www.argostherapeutics.com

Therapeutic Focus: Oncology, Infectious Diseases

Development Status: Phase 3, Phase 2b

Corporate Partners: NA

Funds Raised: NA

Presenter: Jeff Abbey, President & CEO

Aridis Pharmaceuticals, Inc.

Aridis is a clinical-stage biotech company developing anti-infective candidates for lung infections and a human mAb discovery platform. It has two human mAbs in Phase 2a trials for acute pneumonia and two anti-infective candidates at IND.

Location: San Jose, California United States

Year Established: 2005

Website: www.aridispharma.com

Therapeutic Focus: Infectious Diseases, Anti-Infectives, Monoclonal Antibodies, Acute pneumonia, Cystic fibrosis

Development Status: Phase 1a; Phase 2a

Corporate Partners: NA

Funds Raised: approx. \$40 M non-dilutive + \$7 M private

Presenter: Vu L. Truong, PhD, CEO

Asceneuron SA

Asceneuron is a preclinical biopharmaceutical company developing therapeutics for orphan tauopathies and improved symptomatic drugs for Alzheimer's disease. The company expects that its lead small molecule tau program will enter clinical development in early 2015.

Location: Lausanne, Switzerland

Year Established: 2012

Website: asceneuron.com

Therapeutic Focus: Orphan Tauopathies (PSP), Alzheimer's Disease

Development Status: Lead asset Preclinical, anticipated Phase 1 in 2015

Corporate Partners: Merck Serono Ventures

Funds Raised: USD \$6.2 M seed raised in 2012; USD \$0.4 M grants in 2013/14

Presenter: Dirk Beher, PhD, Founder & CEO

Asterias Biotherapeutics, Inc. (NYSE MKT: AST)

Asterias develops products based on its core technology platforms of pluripotent stem cells and allogeneic dendritic cell immunotherapies. It has two clinical-stage programs, one AST-OPC1 for spinal cord injuries and one AST-VAC2 for lung cancer.

Location: Menlo Park, California United States

Year Established: 2012

Website: www.asteriasbiotherapeutics.com

Therapeutic Focus: Oncology, Neurology, Regenerative Medicine

Development Status: Phase 1/2a

Corporate Partners: NA

Funds Raised: \$30-40 M non-dilutive funding for programs from California Institute of Regenerative Medicine and Cancer Research United Kingdom. \$25M of cash raised to date

Presenter: Katharine E. Spink, PhD, COO

Athersys, Inc. (NASDAQ: ATHX)

Athersys is a clinical-stage cell therapy company targeting neurological conditions, cardiovascular disease, inflammatory and immune disorders. Its lead programs include a Phase 2 study in ischemic stroke and a Phase 2 study in acute myocardial infarction.

Location: Cleveland, Ohio United States

Year Established: 1995

Website: www.Athersys.com

Therapeutic Focus: Neurology, Cardiovascular, Inflammatory/Immune Disorders; Stem Cell Therapy

Development Status: Phase 2

Corporate Partners: Pfizer, Inc.; RTI; BMS

Funds Raised: Funding from capital markets; license fees, royalties, other commercial revenues; grant proceeds

Presenter: BJ Lehmann, President & COO

Atossa Genetics Inc. (NASDAQ: ATOS)

Atossa Genetics is a commercial-stage company targeting the treatment of breast health through the development of laboratory services, medical devices and therapeutics. It has two aspirators on the market in the US and OUS.

Location: Seattle, Washington United States

Year Established: 2009

Website: www.atossagenetics.com

Therapeutic Focus: Oncology

Development Status: Marketed

Corporate Partners: McKesson, ThermoFisher Scientific, Millennium Healthcare Solutions, Rhenus Logistics, BioVentive, Aspire

Funds Raised: Approx. \$45 M to date

Presenter: Steven C. Quay, MD, PhD, President & CEO

Attana AB

Attana AB is a commercial-stage company that develops and markets biosensors to predict drug efficacy for pharmaceutical and diagnostic markets and for use by academic societies.

Location: Stockholm, Sweden

Year Established: 2002

Website: www.attana.com

Therapeutic Focus: Label-Free Biosensor for Prediction of Drug Efficacy

Development Status: Products on the market

Corporate Partners: NA

Funds Raised: NA

Presenter: Teodor Aastrup, CEO

AuraSense Therapeutics, LLC

This early-stage biopharmaceutical company is developing a new class of nucleic acid it calls Spherical Nucleic Acid (SNA). SNAs provide a 3D presentation of oligonucleotides, which are able to enter cells and tissues without the use of transfection agents. It expects to file INDs in 2015.

Location: Skokie, Illinois United States

Year Established: 2011

Website: www.aurasensetherapeutics.com

Therapeutic Focus: Immuno-Oncology, Inflammation, Dermatology

Development Status: Planned IND in 2015

Corporate Partners: NA

Funds Raised: \$23 M; \$13+ M in 2014

Presenter: David Giljohann, PhD, CEO

Avexxin AS

Avexxin is a clinical-stage biopharmaceutical company developing and commercializing small molecule therapeutics for patients with chronic inflammatory conditions. It has a topical treatment for psoriasis in clinical development and preclinical assets for the treatment of rheumatoid arthritis.

Location: Trondheim, Norway

Year Established: 2005

Website: www.avexxin.com

Therapeutic Focus: Inflammation, Psoriasis, Dermatitis, Rheumatoid Arthritis, Glomerular Nephritis/Renal

Development Status: AVX001: Phase 1/2a; AVX002, AVX235: Preclinical

Corporate Partners: NA

Funds Raised: approx. €12 M to date; primary investor Sarsia Seed in Norway

Presenter: Mikael Øerum, Chairman & CEO

Aviara Pharmaceuticals, Inc.

Aviara develops small molecule pharmaceuticals to enhance the effectiveness of cell therapies and treat inflammatory diseases. Its lead clinical candidate is being developed for the mobilization of hematopoietic stem cells to the peripheral blood for autologous transplant in patients with leukemia or lymphoma.

Location: Houston, Texas United States

Year Established: 2010

Website: www.aviarapharma.com

Therapeutic Focus: Cell Therapies, Regenerative Medicine, Inflammation,

Development Status: IND for AVA4746

Corporate Partners: Pfizer, Texas Heart Institute

Funds Raised: \$250,000 startup funding

Presenter: Patrick Ward, COO

Azevan Pharmaceuticals, Inc.

Azevan's first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of stress-related CNS disorders, including neuropsychiatric symptoms in neurodegenerative disease, intermittent explosive disorder, PTSD and major depression. Its most advanced compound is in Phase 2 trial for intermittent explosive disorder.

Location: Bethlehem, Pennsylvania United States

Year Established: 2005

Website: www.azevan.com

Therapeutic Focus: Intermittent Explosive Disorder, PTSD, Neuropsychiatric symptoms in Neurodegenerative Disease

Development Status: Phase 2 for SRX246 a vasopressin 1a receptor antagonist

Corporate Partners: NA

Funds Raised: Venture funding led by Ascent Biomedical Ventures; non-dilutive funds-NIH grants, other awards

Presenter: Neal Simon, PhD, CEO

AzurRx BioPharma, Inc.

AzurRx BioPharma is a recently founded biotechnology company developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. Our MS1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early-stage research being conducted for the prevention of hospital-acquired infections.

Location: New York, New York United States

Year Established: 2014

Website: www.azurrx.com

Therapeutic Focus: Gastroenterology, Chronic Pancreatitis, Cystic Fibrosis, Infectious Diseases, Nosocomial Infections, Recombinant Enzyme, Non-Systemic Biologics

Development Status: MS1819: Phase 2b

Corporate Partners: Mayoly-Spindler

Funds Raised: \$15 M in clinical development

Presenter: Johan Spoor, Chairman

BEAT BioTherapeutics Corp.

BEAT BioTherapeutics is a preclinical-stage company developing a gene therapy for the treatment of heart failure.

Location: Seattle, Washington United States

Year Established: 2008

Website: www.beatbiotherapeutics.com

Therapeutic Focus: Heart Failure

Development Status: Pre-IND

Corporate Partners: NA

Funds Raised: \$4 M in convertible notes (angel investors), will convert into Series A preferred financing

Presenter: Michael Kranda, CEO

Bell Biosystems, Inc.

Bell Biosystems is a preclinical synthetic biology company developing living biological tools that add complex function to cells. Its lead product is a living magnetic contrast agent to address economic and technical roadblocks in the clinical practice of cell therapies.

Location: San Francisco, California United States

Year Established: 2009

Website: www.bellbiosystems.com

Therapeutic Focus: Cell Therapy

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: ~\$3 M from investors and ~\$1.7 M from grants

Presenter: Caleb B. Bell III, PhD, Founder & CEO

Benitec Biopharma (ASX: BLT)

Benitec Biopharma develops treatments for chronic and life-threatening conditions based on its gene-silencing technology. Its clinical pipeline is focused on Hep C, Hep B, lung cancer and wet age-related macular degeneration. Its lead candidate targets Hep C and is in Phase1/2a.

Location: Sydney, New South Wales Australia

Year Established: 1997

Website: www.benitec.com

Therapeutic Focus: Hepatitis C, Hepatitis B, Lung Cancer, Wet Age-Related Macular Degeneration, Orphan Genetic Disease, Oculopharyngeal Muscular Dystrophy.

Development Status: Patient dosing of TT-034 Phase 1/2a clinical trial in Hepatitis C & B, Preclinical; Non Small Cell Lung Cancer, Preclinical (Phase 1/2a being prepared)

Corporate Partners: Lodge Partners

Funds Raised: \$31.5 M from US institutions, Feb. 2014; June 2013, Lodge Partners raised \$10 M; Benitec \$7 M, May 2011

Presenter: Dr. Peter French, Managing Director & CEO

Bio-Path Holdings, Inc. (NASDAQ: BPTH)

This a clinical-stage company developing therapeutic products using its liposomal delivery technology designed to systemically distribute nucleic acid drugs with a simple intravenous transfusion. Its lead candidate will start a Phase 2 study for blood cancers and is in preclinical studies for triple negative and inflammatory breast cancers.

Location: Houston, Texas United States

Year Established: 2007

Website: www.biopathholdings.com

Therapeutic Focus: Oncology

Development Status: Commencement of Phase 2 trial anticipated

Corporate Partners: NA

Funds Raised: NA

Presenter: Peter Nielsen, President & CEO

BioLineRx Ltd. (NASDAQ: BLRX)

BioLineRx is a clinical-stage biopharmaceutical company that identifies, in-licenses and develops therapeutic candidates. It develops assets through preclinical or clinical-stages and then partners with pharmaceutical companies for advanced clinical development or commercialization.

Location: Jerusalem, Israel

Year Established: 2003

Website: www.biolinerx.com

Therapeutic Focus: Oncology, Immunology

Development Status: Phase 2a, Phase 1b, Pivotal

Corporate Partners: Bellerophon, CTTQ Pharmaceuticals, JHL Biotech

Funds Raised: More than \$150 M in several public and private financings

Presenter: Philip Serlin, COO & CFO

Biological Dynamics, Inc.

Biological Dynamics is a clinical-stage diagnostic company focused on cancer treatment response monitoring, as well as diagnostics for other inflammatory diseases. It expects to receive a CE mark and 510k clearance in 2016.

Location: San Diego, California United States

Year Established: 2008

Website: biologicaldynamics.com

Therapeutic Focus: Cancer Treatment Response Monitoring Diagnostics

Development Status: In-development, anticipate CE mark and 510(k) approval by early 2016

Corporate Partners: Seeking additional partners; UCSD Moores Cancer Center

Funds Raised: \$18 M

Presenter: Raj Krishnan, PhD, Co-Founder & CEO

BioMarker Strategies, LLC

BioMarker Strategies is a tissue-based cancer diagnostics company that is developing a live tumor testing platform to improve the treatment of cancer.

Location: Rockville, Maryland United States

Year Established: 2006

Website: www.biomarkerstrategies.com

Therapeutic Focus: Solid Tumor Cancer Diagnostics

Development Status: Awarded 2-year \$1.5 million Phase 2 NCI contract in late 2013

Corporate Partners: In discussions with leading pharmaceutical companies. Expect to enter into first two funded commercial collaborations in 2015

Funds Raised: \$9.5 M in equity capital to date; \$4.25 M in non-dilutive funding, National Cancer Institute

Presenter: Jerry Parrott, President & CEO

Bionomics Limited (ASX: BNO)

Bionomics is creating new therapies for the treatment of cancer and diseases of the central nervous system such as anxiety, depression and Alzheimer's based on four platform technologies. Its lead candidate is a solid tumor targeting agent in Phase 2 trials.

Location: Thebarton, South Australia

Year Established: 1999

Website: www.bionomics.com.au

Therapeutic Focus: CNS

Development Status: BNC105 Phase 2; BNC101 preclinical; BNC210 Phase 1

Corporate Partners: Merck & Co, Cooperative Research Centre Cancer Therapeutics

Funds Raised: NA

Presenter: Dr. Deborah Rathjen

Bionure, Inc.

Bionure is a late-preclinical-stage company developing SGK agonists for the treatment of orphan ophthalmologic diseases. Its lead candidate received orphan designation for the treatment of optic neuritis. An IND is expected in 2Q15.

Location: Menlo Park, California United States

Year Established: 2009

Website: www.bionure.com

Therapeutic Focus: Ophthalmology, Rare Diseases

Development Status: Late Preclinical (IND by 2Q15)

Corporate Partners: Myelin Repair Foundation

Funds Raised: \$7 M since foundation in 2009, half dilutive and half non-dilutive

Presenter: Albert G. Zamora, MBA, CEO

BiotecnoL Ltd.

BiotecnoL is a preclinical company developing T and NK-cell activating, multi-targeting antibodies in the immune-oncology field.

Location: Welwyn Garden City, Hertfordshire United Kingdom

Year Established: 2013

Website: www.biotecnoL.com

Therapeutic Focus: Oncology

Development Status: Late Preclinical

Corporate Partners: Chiome, Inc. (Japan)

Funds Raised: USD \$5+ M in a series A; \$3+ M in non-dilutive financing

Presenter: Neill Moray Mackenzie, PhD, Director & CBO

Biotron Limited (ASX: BIT)

Biotron is a mid-stage drug development company targeting Hepatitis C and HIV. Its small molecule antiviral drug has shown good clinical efficacy against HCV. It also has potential to attack HIV viral reservoirs which would contribute to the eradication of HIV.

Location: Sydney, New South Wales Australia

Year Established: 1999

Website: www.biotron.com.au

Therapeutic Focus: Antiviral therapeutics, focused on HIV and Hepatitis C Virus

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: A\$32 M to date

Presenter: Michelle Miller, PhD, Managing Director

Biovest International, Inc.

Biovest International develops and manufactures personalized medicines. Its lead active immunotherapy has successfully completed Phase 2 and Phase 3 clinical trials and is currently undergoing regulatory review for marketing authorization in the EU.

Location: Minneapolis, Minnesota United States

Year Established: 1981

Website: www.biovest.com

Therapeutic Focus: Oncology, HemOnc, Non-Hodgkin Lymphoma, Indolent B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma

Development Status: Phase 3, MAA (EU)

Corporate Partners: NA

Funds Raised: NA

Presenter: Carlos Santos, PhD, CEO

Blend Therapeutics, LLC

Blend develops medicines that overcome the biological barriers that limit the effectiveness of cancer therapeutics. It is advancing a small molecule anticancer drug candidate through preclinical development.

Location: Watertown, Massachusetts United States

Year Established: 2011

Website: www.blendtx.com

Therapeutic Focus: Oncology

Development Status: GLP tox / preclinical

Corporate Partners: NA

Funds Raised: NA

Presenter: Richard Wooster, PhD, President & CSO

BrainStorm Cell Therapeutics (NASDAQ: BCLI)

BrainStorm is a clinical-stage company with a technology for cell-based delivery of neurotrophic factors. Its lead product is in a Phase 2 clinical trial at three US centers for ALS. It is also targeting Parkinson's disease, MS and other CNS diseases.

Location: Hackensack, New Jersey United States

Year Established: 2004

Website: www.brainstorm-cell.com

Therapeutic Focus: Neurology, Cell Therapy, Stem Cells

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: NA

Presenter: Tony Fiorino, MD, PhD, CEO

C4X Discovery (LSE AIM: C4XD)

C4XD is a preclinical company with a platform for small molecule discovery that accurately measures the range and shapes a molecule can take in a solution. The platform is indication independent, however the company is targeting addiction, diabetes and COPD. It has collaborations with AZ, Takeda and Evotec.

Location: Manchester, United Kingdom

Year Established: 2007

Website: www.c4xdiscovery.com

Therapeutic Focus: Addiction, Diabetes, COPD (platform is indication independent)

Development Status: Preclinical

Corporate Partners: AstraZeneca, Takeda, Evotec

Funds Raised: IPO in October 2014 to raise \$17 M

Presenter: Piers Morgan, CEO

Canbex Therapeutics Ltd.

Canbex has a Phase 2-ready compound that it hopes will be the first well-tolerated treatment for uncontrolled muscle movement in multiple sclerosis and other disorders. The compound is an orally active small molecule.

Location: London, United Kingdom

Year Established: 2005

Website: www.canbex.co.uk

Therapeutic Focus: Neurology

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: \$3.2 M Series A closed in April 2013

Presenter: Jesse Schulman, PhD, CEO

Capricor Therapeutics, Inc. (OTCBB: CAPR)

Capricor develops therapeutics for the treatment of cardiovascular disease. Its lead product is an allogeneic adult stem cell therapy for heart disease that is in Phase 2 in ischemic heart disease and Duchenne Muscular Dystrophy.

Location: Los Angeles, California United States

Year Established: 2005

Website: www.capricor.com

Therapeutic Focus: Cardiovascular

Development Status: Phase 2, CAP-1002

Corporate Partners: NA

Funds Raised: approx. \$12.0 M equity; approx. \$39.5 M non-dilutive capital

Presenter: Linda Marban, PhD, CEO

Capstone Therapeutics Corp (OTCQB: CAPS)

Capstone Therapeutics/LipimetiX Development is a clinical-stage biotechnology company developing a new class of cardiovascular drug. Native Apolipoprotein E is recognized as a fundamental regulator of cholesterol and lipid metabolism. The company's family of Apo E mimetic peptides target orphan, genetic lipid disorders.

Location: Tempe, Arizona United States

Year Established: 1989

Website: www.capstonethx.com

Therapeutic Focus: Cardiovascular Disease

Development Status: Completed Phase 1a, Phase 1b/2a

Corporate Partners: University of Alabama at Birmingham Research Foundation

Funds Raised: \$100 M derived from sale of medical device business

Presenter: Dennis I. Goldberg, PhD

CEL-SCI Corporation (NYSE MKT: CVM)

CEL-SCI is an advanced-stage immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. It is currently conducting a Phase 3 trial for the treatment of head and neck cancer and a Phase 1 study with the US Navy in HIV/HPV co-infected patients.

Location: Vienna, Virginia United States

Year Established: 1983

Website: www.cel-sci.com

Therapeutic Focus: Cancer Immunotherapy; Infectious Diseases

Development Status: Phase 3, Phase 1, Preclinical

Corporate Partners: Teva Pharmaceutical Industries Ltd., Ergomed Clinical Research Ltd., and Orient Europharma Co. Ltd.

Funds Raised: approx. \$250 M

Presenter: Geert Kersten, CEO

Cell Source, Inc. (OTCBB: CLCS)

Cell Source is a preclinical-stage immunotherapy and regenerative medicine company. Its technology relates to the regulation of immune tolerance to effectively treat blood cancers and nonmalignant congenital diseases.

Location: Tel Aviv, Israel

Year Established: 2011

Website: www.cell-source.com

Therapeutic Focus: Immune Therapy; Regenerative Medicine

Development Status: About to commence Phase 1/2 human clinical trials

Corporate Partners: Yeda Research and Development Limited, the commercial arm of the Weizmann Institute of Technology in Israel

Funds Raised: \$6 M

Presenter: Itamar Shimrat, CEO

Cell Therapy Limited

Cell Therapy is a clinical-stage cell therapy company that has completed a Phase 2a trial demonstrating in situ myocardial regeneration with clinical and statistically significant improvement in LVEF, scar reduction and improved quality of life.

Location: Cardiff, Wales United Kingdom

Year Established: 2009

Website: www.CellTherapyLtd.com

Therapeutic Focus: Heart Failure

Development Status: Phase 2

Corporate Partners: TBA

Funds Raised: Confidential

Presenter: Ajan Reginald, Executive Director & CEO

Cellceutix Corporation (OTCBB: CTIX)

Cellceutix is a therapeutic antibody company that recently completed a Phase 2 study. The company has compounds in clinical trials for cancers, psoriasis and oral mucositis. Additional trials are planned for diabetic foot infections, eye and ear infections, anti-fungal and gram-negative drug resistant bacteria.

Location: Beverly, Massachusetts United States

Year Established: 2007

Website: www.cellceutix.com

Therapeutic Focus: Infectious Diseases, Oncology, Dermatology

Development Status: Phase 1, Phase 1b, Phase 2

Corporate Partners: NA

Funds Raised: \$30 M

Presenter: Leo Ehrlich, CEO

Cellectar Biosciences, Inc. (NASDAQ: CLRB)

Cellectar is a Phase 1 stage oncology company that uses a technology that permits selective delivery of a variety of agents to cancer cells. Its lead candidate is a Phase 2 small molecule currently being evaluated in patients with glioblastoma.

Location: Madison, Wisconsin United States

Year Established: NA

Website: www.cellectar.com

Therapeutic Focus: Oncology

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: \$45+ M with \$13.5 M raised in 2014

Presenter: Dr. Simon Pedder, CEO

Cellular Biomedicine Group Inc. (NASDAQ: CBMG)

Cellular Biomedicine is a clinical-stage regenerative medicine and immune cell company with operations in China. Its focus is aging diseases and cancer in the Chinese market and expects to have Phase 2a interim data on its lead product for knee osteoarthritis in 1Q15.

Location: Palo Alto, California United States

Year Established: 2009

Website: www.cellbiomedgroup.com

Therapeutic Focus: Regenerative Cellular Medicine, Osteoarthritis, Cancer Immune Cell Therapy

Development Status: Knee Osteoarthritis: Phase 2b interim data in 1Q15; Phase 2a, 48 week data Dec. 2014

Corporate Partners: NA

Funds Raised: \$10+ M in 2014; \$40+ M to date

Presenter: Dr. William Cao, CEO

CereSpir Incorporated

CereSpir's lead product has completed a Phase 2 study in people with mild cognitive impairment, and the company is currently finalizing the design of the Phase 3 clinical protocol in consultation with KOLs and the FDA. It aims to initiate Phase 3 trials in 2015.

Location: New York, New York United States

Year Established: 2013

Website: www.cerespir.com

Therapeutic Focus: Neurodegeneration, Mild Cognitive Impairment

Development Status: Phase 2 completed

Corporate Partners: Chiesi Farmaceutici S.p.A.

Funds Raised: \$2 M; \$60+ M previously invested in program

Presenter: Daniel G. Chain, Founder, President & CEO

Cesca Therapeutics, Inc. (NASDAQ: KOOL)

Cesca Therapeutics is a clinical company focused on cell-based therapeutics for use in regenerative medicine. Its lead therapeutic technology platform is in trials for the treatment of acute myocardial infarction, critical limb ischemia and orthopedic injuries.

Location: Rancho Cordova, California United States

Year Established: 1986

Website: www.cescatherapeutics.com

Therapeutic Focus: Cell-Based Therapeutics

Development Status: NA

Corporate Partners: NA

Funds Raised: NA

Presenters: Robin C. Stracey, Interim CEO & Director and Dan T. Bessey, CFO

CEVEC Pharmaceuticals GmbH

CEVEC is a clinical-stage company developing CAP-based treatments for various indications including inherited angioedema, lung emphysema and inflammatory diseases.

Location: Cologne, Germany

Year Established: 2003

Website: www.cevec.com

Therapeutic Focus: Inherited Angioedema, Lung Emphysema, Inflammatory Diseases

Development Status: Preclinical (C1 Inh and AAT), Phase 1 (hAP)

Corporate Partners: Paragon Bioservices, Baltimore; Sirion Biotech, Munich; Genibet, Lisbon

Funds Raised: €18 M

Presenter: Dr. Hartmut Tintrup, CBO

Chembio Diagnostics, Inc. (NASDAQ: CEMI)

Chembio is a commercial-stage company that develops, manufactures, licenses and markets rapid diagnostic tests in the point-of-care testing market. It markets a branded test for HIV and is developing diagnostic tests for Ebola, dengue fever and a specific cancer.

Location: Medford, New York United States

Year Established: 2004

Website: chembio.com

Therapeutic Focus: Infectious Disease

Development Status: On the market

Corporate Partners: FIOCRUZ; Alere; Bio-Rad; LabTest; RVR; Integrated BioTherapeutics, Inc. and several undisclosed partners

Funds Raised: \$5.5 M in 2013

Presenter: John Sperzel, President & CEO

Chronos Therapeutics Limited

Chronos is a clinical-stage company focused on diseases of aging, neurodegeneration and osteoporosis. Its lead compound with target indications for osteoporosis and ALS is in Phase 2 a/b clinical trials.

Location: Oxford, Oxfordshire United Kingdom

Year Established: 2009

Website: chronotherapeutics.com

Therapeutic Focus: Diseases of Aging, Neurodegeneration, ALS, AD, PD, FTD, Osteoporosis

Development Status: Preclinical proof of concept, Phase 1b, Phase 2a/b

Corporate Partners: Confidential

Funds Raised: \$20+ M since 2009, with \$13 M since Dec. 2013

Presenter: Huw Jones, PhD, CEO

ContraFect Corp. (NASDAQ: CFRX)

ContraFect is a preclinical biopharmaceutical company that discovers and develops therapeutic protein and antibody products for drug-resistant infectious diseases. It uses lysine and antibody platforms to target conserved regions of either bacteria or viruses.

Location: Yonkers, New York United States

Year Established: 2008

Website: www.contrafect.com

Therapeutic Focus: Infectious Disease

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: Approx. \$100 M, with \$41.3 M in gross proceeds from IPO in 2014

Presenter: Julia P. Gregory, CEO

ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV)

ContraVir is a development-stage biopharmaceutical company that discovers and develops targeted antiviral therapies. Its lead candidate is an orally available treatment for herpes zoster, or shingles, that is in Phase 2b clinical trials.

Location: Edison, New Jersey United States

Year Established: 2013

Website: www.contravir.com

Therapeutic Focus: Virology

Development Status: Phase 2b

Corporate Partners: NA

Funds Raised: \$12 M

Presenter: James Sapirstein, CEO

Corbus Pharmaceuticals, Inc. (OTCQB: CRBP)

Corbus is a clinical-stage biopharmaceutical company that develops therapies to treat inflammatory-fibrotic diseases with clear unmet needs. Its lead product candidate, an oral anti-inflammatory drug, is scheduled to start Phase 2a trials for cystic fibrosis and systemic scleroderma in 2015.

Location: Norwood, Massachusetts United States

Year Established: 2009

Website: www.corbuspharma.com

Therapeutic Focus: Cystic Fibrosis, Systemic Sclerosis also known as Scleroderma

Development Status: Pre-IND: Preparing to file IND for Resunab to initiate Phase 2 trials in cystic fibrosis and scleroderma in 2015

Corporate Partners: NA

Funds Raised: \$10.3+ M Series B private financing, May 2014; Preparing for IPO end of 2014; \$1.3 M in NIH grants.

Presenter: Yuval Cohen, PhD, CEO

Cornerstone Pharmaceuticals Inc.

This clinical-stage, oncology-focused pharmaceutical company has a platform that targets and disrupts energy metabolism in cancer cells. Its lead product is in clinical trials for solid tumors and hematologic malignancies.

Location: Cranbury, New Jersey United States

Year Established: 1999

Website: www.cornerstonepharma.com

Therapeutic Focus: Oncology, Cancer Cell Metabolism, CPI-613

Development Status: Clinical-stage

Corporate Partners: NA

Funds Raised: \$50 M to date, private financing

Presenter: Steve Carchedi, CEO

Cortendo AB (NOTC-A: CORT)

Cortendo commercializes medicines for orphan endocrine disorders. Its lead product is currently being studied in a Phase 3 global trial for the treatment of Cushing's syndrome.

Location: Radnor, Pennsylvania United States

Year Established: 1996

Website: www.cortendo.com

Therapeutic Focus: Orphan Endocrine Diseases

Development Status: Phase 3

Corporate Partners: NA

Funds Raised: NA

Presenter: Matt Pauls, President & CEO

Cortex Pharmaceuticals Inc. (OTCBB: CORX)

Cortex is a biopharmaceutical company developing drug treatments for a variety of breathing disorders. Its lead programs, one for the treatment of obstructive sleep apnea and another for the treatment of drug-induced respiratory depression and central sleep apnea, have successfully completed Phase 2 clinical trials.

Location: Glen Rock, New Jersey United States

Year Established: 1987

Website: www.cortexpharm.com

Therapeutic Focus: Respiratory Disorders

Development Status: Phase 2A studies for dronabinol and ampakines; Phase 2B clinical trial in 120 patients expected 3Q14; two Phase 2 ampakine studies in 2015.

Corporate Partners: NA

Funds Raised: NA

Presenter: Arnold Lippha PhD, Chairman, President & CEO

Cortice Biosciences Incorporated

Cortice Biosciences is a clinical-stage company developing treatments for large and rare oncologic and neurologic disease indications. Its lead programs address the treatment of brain cancers and neurodegenerative diseases and neurotransmitter pathway modulation for the treatment of cognitive impairment.

Location: New York, New York United States

Year Established: 2008

Website: www.corticebiosciences.com

Therapeutic Focus: Oncology, Neurology

Development Status: TPI 287: Phase 1 and Phase 2

Corporate Partners: NA

Funds Raised: NA

Presenter: George Farmer, PhD, CEO

Crescendo Biologics Ltd.

Crescendo Biologics is a preclinical company that has developed an antibody fragment platform. It has recently completed a Series A financing that will allow it to develop a topical biologic for psoriasis and as well as discovery Phase oncology products.

Location: Cambridge, United Kingdom

Year Established: 2008

Website: www.crescendobiologics.com

Therapeutic Focus: Psoriasis, Oncology (T cell engagers/ADCs)

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: \$32.5 M Series A in 2014, total of \$40 M since 2008

Presenter: Mike Romanos, PhD, CEO

Cristal Therapeutics

This early-clinical-stage nanomedicines company targets oncology and inflammation. It expects to start a clinical trial for its lead product in 2Q15 with Phase 2a to be initiated in 2Q16.

Location: Maastricht, The Netherlands

Year Established: 2011

Website: www.cristaltherapeutics.com

Therapeutic Focus: Oncology, Inflammation

Development Status: Phase 1/2a study of CriPec docetaxel commences 2Q15

Corporate Partners: Planning at least two collaborations in 2015

Funds Raised: €5 M VC since inception; Additional €4 M raised as grants

Presenter: Joost J.M. Holthuis, PhD, CEO

Critical Outcome Technologies Inc. (TSX.V: COT)

COTI is a biopharmaceutical company using machine learning to rapidly develop targeted therapies. Our lead program, COTI-2, restores normal cell signaling in cancer patients with p53 mutations. COTI's biological simulation platform, CHEMSAS®, accelerates the drug discovery, optimization and validation of small molecules to solve unmet patient needs.

Location: London, Ontario Canada

Year Established: 2006

Website: www.criticaloutcome.com

Therapeutic Focus: Cancers, Methicillin-Resistant Staph Aureus (MRSA), HIV, Multiple Sclerosis

Development Status: COTI-2: Phase 1 study commences early 2015

Corporate Partners: NA

Funds Raised: Common share equity raises of ~ CAD \$18.6 M private placements, warrant exercises, and option exercises

Presenter: Dr. Wayne Danter, President & CEO

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Cyclacel's lead drug candidate in a Phase 3 trial that is now over 90% enrolled and is being conducted under an SPA with the FDA as a front-line treatment for AML in the elderly. The drug is also being studied for MDS and solid tumors in combination with its CDK inhibitor.

Location: Berkeley Heights, New Jersey United States

Year Established: 1997

Website: www.cyclacel.com

Therapeutic Focus: Oncology, Hematology, Inflammation

Development Status: Phase 3

Corporate Partners: Daiichi-Sankyo

Funds Raised: NA

Presenter: Spiro Rombotis, President & CEO

Cynapsus Therapeutics Inc. (OTCQX: CYNAP)

Cynapsus is a specialty pharmaceutical company developing a sublingual thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease. Its lead candidate is a reformulation of the only approved drug to rescue patients from "off" episodes. It expects to submit an NDA in 2016.

Location: Toronto, Ontario Canada

Year Established: 2006

Website: www.cynapsus.ca

Therapeutic Focus: Parkinson's, Acute Rescue of Motor Fluctuations

Development Status: Phase 2, completion of regulatory requirements late 2015

Corporate Partners: NA

Funds Raised: Since 2009, CAD \$1.4 M in non-dilutive Michael J. Fox Foundation grant; and CAD \$36.3 M in equity

Presenter: Anthony J. Giovinazzo, MBA, CDir, ACC, President & CEO

Cytograft Tissue Engineering

Cytograft is a late stage regenerative medicine and tissue engineering company. It currently has three programs in human clinical trials: Phase 2b/3 vascular graft for hemodialysis access; Phase 1/2 vascular graft for lower limb bypass; Phase 1/2 dermal filler for smile lines and facial wrinkles.

Location: Novato, California United States

Year Established: 2000

Website: www.cytograft.com

Therapeutic Focus: Hemodialysis Access, Dermal Filler, Lower Limb Bypass

Development Status: Phase 2b/3: Vascular Graft for Hemodialysis Access; Phase 1/2: Vascular Graft for Lower Limb Bypass; Phase 1/2: Dermal Filler

Corporate Partners: NA

Funds Raised: NA

Presenter: Dr. Todd McAllister, PhD, Chairman & CEO

Cytori Therapeutics, Inc. (NASDAQ: CYTX)

Cytori is a clinical-stage cell therapy company developing treatments for cardiovascular disease and soft tissue injuries and burns. It is targeting the treatment of chronic ischemic heart failure through internal clinical development efforts and to develop a treatment for thermal burns combined with radiation injury under a contract from BARDA.

Location: San Diego, California United States

Year Established: 1996

Website: www.cytori.com

Therapeutic Focus: Thermal Burns (BARDA), Cardiovascular Disease

Development Status: Phase 2 (cardiac), in IDE submission process for pilot clinical trial (thermal burns)

Corporate Partners: BARDA, Lorem Vascular

Funds Raised: \$200+ M since inception

Presenter: Marc H. Hedrick, MD, President & CEO

DARA BioSciences, Inc. (NASDAQ: DARA)

DARA is a commercialized oncology supportive care pharmaceutical company that offers a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage the side effects of treatment.

Location: Raleigh, North Carolina United States

Year Established: 2002

Website: www.darabio.com

Therapeutic Focus: Oncology, Oncology Supportive Care

Development Status: Six marketed products: one in Phase /2b

Corporate Partners: Helsinn Healthcare / Mission Pharmacal

Funds Raised: \$70 M, primarily through registered direct offerings and private placements of equity securities

Presenter: David J. Drutz, MD, Executive Chairman & CMO

DelMar Pharmaceuticals, Inc. (OTCQX: DMPI)

DelMar Pharmaceuticals develops and commercializes proven cancer therapies in new orphan drug indications. Its lead drug candidate is currently undergoing clinical trials in the US as a potential treatment for refractory glioblastoma multiforme.

Location: Vancouver, British Columbia Canada

Year Established: 2010

Website: www.delmarpharma.com

Therapeutic Focus: Oncology, Glioblastoma Multiforme, Non-Small Cell Lung Cancer

Development Status: Phase 1/2: Glioblastoma Multiforme; Marketed CML and Marketed Lung Cancer (both China only)

Corporate Partners: Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. (development partner, China only)

Funds Raised: \$17 M since inception, including \$10.5 M private placement as part of public listing transaction (RTO) in 2013

Presenter: Jeffrey Bacha, President & CEO

Dipexium Pharmaceuticals (NASDAQ: DPRX)

Dipexium is conducting pivotal Phase 3 trials on its topical antibiotic cream targeting the treatment of mild infections of diabetic foot ulcers as well as other skin infections including those caused by resistant bacteria or “super-bugs.”

Location: New York, New York United States

Year Established: 2010

Website: www.dipexiumpharmaceuticals.com

Therapeutic Focus: Topical Skin Infections

Development Status: Ongoing pivotal Phase 3 studies.

Corporate Partners: NA

Funds Raised: \$47.8 M

Presenter: David P. Luci, President & CEO

EIP Pharma, LLC

EIP Pharma is developing an investigational drug that specifically targets inflammation in the brain, which recent testing indicates is a critical driver of disease progression in Alzheimer’s disease. The company expects to initiate its first Phase 2 clinical trial in patients with Alzheimer’s in early 2015.

Location: Cambridge, Massachusetts United States

Year Established: 2010

Website: www.eipharma.com

Therapeutic Focus: Neurology

Development Status: Phase 2a

Corporate Partners: NA

Funds Raised: Seed funded by founder; Approx. \$500K

Presenter: John Alam, MD, Founder & CEO

Elastagen Pty. Ltd.

Elastagen is a clinical-stage medical company that is using the human protein elastin to naturally rejuvenate, repair or regenerate damaged and aged tissues with applications in aesthetics, scar remodelling, wound repair and surgical adhesives.

Location: Sydney, New South Wales Australia

Year Established: 2005

Website: www.elastagen.com

Therapeutic Focus: Dermatology, Wound Repair, Aesthetics, Surgical biomaterial

Development Status: Phase 2 (Medical Device)

Corporate Partners: Not disclosed

Funds Raised: Not Disclosed

Presenter: Robert Daniels, Director & CEO

Ellume

Ellume is a consumer diagnostic company developing a non-invasive, ultra-sensitive home test for influenza. Validation trials are planned for 2015 and it expects to market the product in 2016 with a suggested retail price of between USD \$20-\$25.

Location: East Brisbane, Queensland Australia

Year Established: 2010

Website: ellume.com.au

Therapeutic Focus: Home Influenza Test

Development Status: Clinical Validation 2015

Corporate Partners: NA

Funds Raised: NA

Presenter: Dr. Sean Parsons, Founder & Managing Director

Embera NeuroTherapeutics, Inc.

Embera is developing a patented drug combination to address smoking cessation and cocaine dependence. The FDA has completed its review of the company's IND submission and a Phase 1 study in otherwise healthy smokers is set to proceed.

Location: Sudbury, Massachusetts United States

Year Established: 2007

Website: www.emberaneuro.com

Therapeutic Focus: CNS, Respiratory, Neuro-Psychiatric Disorders

Development Status: Phase 1

Corporate Partners: Ongoing discussions with 16 pharma companies interested in entering into a transaction upon completion of Phase 2 POC studies

Funds Raised: \$10 M to date, \$6 M in equity capital, \$4 M in non-dilutive grants

Presenter: Bob Linke, President & CEO

EnGeneIC Limited

EnGeneIC Limited is a clinical-stage biopharmaceutical company that aims to commercialize products for the targeted delivery of drugs and functional nucleic acids used in the treatment of cancer.

Location: Sydney, New South Wales Australia

Year Established: 2000

Website: www.engageic.com

Therapeutic Focus: Oncology, Brain Cancer, Nanocell Technology

Development Status: Phase 1; second Phase 1; commenced a Phase 1/2a trial

Corporate Partners: NA

Funds Raised: Equity Funds \$49 M, R&D Grants \$13 M, Other \$7 M

Presenter: Dr. Himanshu Brahmhatt, Co-Founder & Joint Managing Director

Ennaid Therapeutics

Ennaid is a preclinical company that is developing cures for dengue virus, a mosquito-borne disease. The company expects that with its fast track development program its lead product will be on the market in 4 to 6 years.

Location: New York, New York United States

Year Established: 2012

Website: www.ennaidthera.com

Therapeutic Focus: Infectious Diseases

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: \$175,000 seed money

Presenter: Darnisha Harrison, Founder & CEO

Enumeral Biomedical Holdings (OTCQB: ENUM)

Enumeral is a preclinical-stage company developing antibody immunotherapies for cancer, inflammatory and autoimmune diseases. Its platform enables the measurement of drug effects in a patient-specific manner.

Location: Cambridge, Massachusetts United States

Year Established: 2011

Website: www.enumeral.com

Therapeutic Focus: Oncology, Inflammation, Immunology

Development Status: Preclinical

Corporate Partners: Historical: Sanofi, Crucell (J&J), Novartis, Celgene Cellular Therapeutics. Multiple now in discussion

Funds Raised: ~\$11.2 M while private; \$21.5 M in PIPE/Reverse Merger

Presenter: Arthur H. Tinkelenberg, PhD, CEO

Epirus Biopharmaceuticals, Inc. (NASDAQ: EPRS)

Epirus is a biopharmaceutical company that develops and commercializes biosimilar monoclonal antibodies. It is targeting indications in immunology and inflammation. It has one product marketed in India and another in Phase 3 trials.

Location: Boston, Massachusetts United States

Year Established: 2011

Website: epirusbiopharma.com

Therapeutic Focus: Immunology, Inflammation

Development Status: BOW015: Marketed India, Phase 3 Global; BOW050 & BOW070: Preclinical

Corporate Partners: Livzon Mabpharm Inc.; Ranbaxy Laboratories Limited

Funds Raised: \$75 M

Presenter: Amit Munshi, President & CEO

Etubics Corporation

Etubics is a clinical-stage company with immunotherapy programs in oncology and infectious diseases including Ebola, universal influenza and Lassa. Its platform technology has broad applications to induce cell mediated and antibody responses and allows for rapid development vaccines.

Location: Seattle, Washington United States

Year Established: 2006

Website: www.etubics.com

Therapeutic Focus: Oncology (Colorectal, Breast and HPV induced Cancers); Infectious Disease Vaccines (Ebola Virus, Universal Influenza Virus, Lassa)

Development Status: Phase 2b

Corporate Partners: NA

Funds Raised: \$19 M, grants, contracts; \$4 M, investor capital; \$16 M collaborative grants

Presenter: Elizabeth S. Gabitzsch, VP Research

Fate Therapeutics, Inc. (NASDAQ: FATE)

Fate is a clinical-stage biopharmaceutical company that discovers and develops pharmacologic modulators of adult stem cells to treat life-threatening diseases. Its lead candidate is in a Phase 2 clinical trial.

Location: San Diego, California United States

Year Established: 2007

Website: www.fatetherapeutics.com

Therapeutic Focus: Hematologic Malignancies, Inherited Metabolic Disorders, Muscle Disorders

Development Status: Phase 2 (PROHEMA®)

Corporate Partners: NA

Funds Raised: NA

Presenter: Christian Weyer, MD, MAS, President & CEO

Fibrocell Science, Inc. (NASDAQ: FCSC)

Fibrocell is a clinical-stage company that uses autologous fibroblasts to treat rare skin diseases. Its lead orphan candidate uses genetically modified fibroblasts is in late-stage preclinical development for recessive dystrophic epidermolysis bullosa. A Phase 2 for a second compound is in progress for vocal cord scarring.

Location: Exton, Pennsylvania United States

Year Established: 2009

Website: www.fibrocellscience.com

Therapeutic Focus: Rare Skin and Connective Tissue Diseases

Development Status: RDEB Orphan Drug Status, Q214; Proof of Concept Animal Study Q414; Phase 2, Q414. RDEBN IND Filed-1H15; Phase 1 initiated-2H15

Corporate Partners: Intrexon Corporation

Funds Raised: \$100+ M

Presenter: David Pernock, Chairman & CEO

FLAG Therapeutics, Inc.

FLAG is a preclinical company with two classes of small molecule oncology therapeutics. One has both broad antiangiogenic inhibition and anticancer effects and is being developed as a treatment of glioblastoma. The class is selective to the FR-Alpha receptor which is unique to certain ovarian, NSCLC, colon and kidney cancers.

Location: Raleigh, North Carolina United States

Year Established: 2013

Website: www.FlagTherapeutics.com

Therapeutic Focus: Oncology

Development Status: preclinical (IND filing within 1 year)

Corporate Partners: NA

Funds Raised: NA

Presenter: Frank L Sorgi, PhD , President & CEO

Fusion Pharmaceuticals LLC

Fusion Pharmaceuticals is a clinical-stage company developing precision radiopharmaceuticals for the diagnosis and treatment of human cancers that are currently untreatable. Its lead product combines an alpha radionuclide with the precise targeting of an antibody to cause selective cytotoxicity of tumor cells.

Location: Hamilton, Ontario Canada

Year Established: 2014

Website: www.fusionpharma.com

Therapeutic Focus: Oncology

Development Status: Phase 1 ongoing

Corporate Partners: NA

Funds Raised: NA

Presenter: Frank Gleeson, President

Galmed Pharmaceuticals (NASDAQ: GLMD)

Galmed is a clinical-stage biopharmaceutical company developing and commercializing a once-daily, oral therapy for the treatment of liver disease. Its lead product is in Phase 2b clinical trials.

Location: Tel Aviv, Israel

Year Established: 2000

Website: www.galmedpharma.com

Therapeutic Focus: Liver Disease, Metabolic Syndrome, Obesity, Glucose Intolerance

Development Status: Phase 2b

Corporate Partners: NA

Funds Raised: \$72 M: \$28 M private, pre-IPO; \$44 M at IPO (March 2014)

Presenter: Allen Baharaff, CEO

Genomic Expression Inc.

Genomic Expression is a diagnostics company developing a pipeline of diagnostics for cancer that take advantage of next generation sequencing technology. It is launching its first products in 2015.

Location: New York, New York United States

Year Established: 2009

Website: www.genomicexpression.com

Therapeutic Focus: Oncology

Development Status: Launch

Corporate Partners: 17 beta testers and are moving the first to MTA

Funds Raised: \$2 M

Presenter: Gitte Pedersen, CEO

gIcare Pharma Inc.

gIcare Pharma, Inc. is a clinical-stage company targeting gastroenterology and pain management. Its lead candidate is a colonic analgesic drug to manage visceral pain during sedation-free colonoscopy.

Location: Montreal-Ouest, Quebec Canada

Year Established: 2011

Website: www.gicarepharma.com

Therapeutic Focus: Gastroenterology, Pain Management

Development Status: Phase 2a completed

Corporate Partners: NA

Funds Raised: \$8.7 M Series A

Presenter: Maxime Ranger, PhD, MBA, CEO

Global Blood Therapeutics, Inc.

GBT is a preclinical-stage biopharmaceutical company developing orally available small molecules for the treatment of severe chronic blood diseases. The company expects to initiate clinical testing in January 2015.

Location: South San Francisco, California United States

Year Established: 2012

Website: globalbloodtx.com

Therapeutic Focus: Severe Chronic Blood Diseases

Development Status: Phase 1/2 to be initiated in January 2015

Corporate Partners: NA

Funds Raised: \$41 M in Series A

Presenter: Ted W. Love, MD, CEO

GO Therapeutics

GO Therapeutics uses technologies and platforms to harness the cancer glycoproteome to generate tumor-specific antibodies for immunotherapies. By making antibodies to hybrid antigens combining a tumor's up-regulated protein express with that of a protein's aberrant glycosylation pattern, it increases the tumor specificity of therapeutic antibodies.

Location: Boston, Massachusetts United States

Year Established: 2009

Website: gotherapeutics.com

Therapeutic Focus: Cancer, Oncology

Development Status: NA

Corporate Partners: NA

Funds Raised: \$2.5 M

Presenter: Thayer White, PhD, CEO & CSO

Gordian Biotechnologies, Inc.

Gordian Biotechnologies is a preclinical-stage company addressing antibiotic resistance by developing a reversible beta-lactamase inhibitor. Its lead product attacks the resistance mechanism of bacteria making them once again susceptible to existing antibiotics.

Location: West Palm Beach, Florida United States

Year Established: 2014

Website: gordianbio.com

Therapeutic Focus: Anti-Infectives

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: Small operating budget raised from founders and angel investor

Presenter: Tony Brazzale, President & CEO

Hansa Medical AB (NASDAQ OMX: HMED)

Hansa Medical is a clinical-stage biopharmaceutical company focused on immunomodulatory enzymes for the treatment of rare immunological conditions. Its lead candidate is currently being evaluated in Phase 2 trials in HLA sensitized transplantation patients. In addition, treatment of several rare autoimmune conditions is being explored.

Location: Lund, Sweden

Year Established: 2007

Website: www.hansamedical.com

Therapeutic Focus: Rare Autoimmune Conditions, Transplantation

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: \$23 M

Presenter: Fredrik Lindgren, President & CEO

Harvard Apparatus Regenerative Technology

NASDAQ: HART

This clinical-stage biotech company is making regenerated tracheas for transplant. Six compassionate care patients have been successfully treated. It has been granted orphan status in the US. The company is developing other esophageal products to treat esophageal cancer.

Location: Holliston, Massachusetts United States

Year Established: 2007

Website: www.hartregen.com

Therapeutic Focus: Tracheal Cancer, Tracheal Stenosis, Esophageal Cancer

Development Status: Expect to file CTA and IND in 2015

Corporate Partners: NA

Funds Raised: Approx. \$30 M

Presenter: David Green, CEO

Helomics Corporation

Helomics is a commercialized personalized healthcare company in the oncology market. In addition to personalized medicine in cancer products, it offers laboratory services including CRO, bioinformatics/databases and companion diagnostics.

Location: Pittsburgh, Pennsylvania United States

Year Established: 1995

Website: www.helomics.com

Therapeutic Focus: Cancer Products; Laboratory Services

Development Status: Commercial stage, revenue-generating

Corporate Partners: NA

Funds Raised: \$60 M

Presenter: Neil J. Campbell, President & CEO

Hydra Biosciences

Hydra is a clinical-stage company that uses TRP ion channels to discover and develop medicines for people with serious diseases. Its most advanced product is being studied for neuropathic pain and asthma, and it expects to begin human clinical trials in the first half of 2015.

Location: Cambridge, Massachusetts United States

Year Established: 2002

Website: hydrabio.com

Therapeutic Focus: Neuropathic Pain, Asthma, Inflammation

Development Status: Phase 1 to commence IH15

Corporate Partners: Boehringer Ingelheim

Funds Raised: \$68M in equity financing since inception.

Presenter: Russell Herndon, President, CEO

iCeutica Inc.

This commercial stage company creates branded medicines in the areas of oncology, respiratory disease, musculoskeletal and connective tissue disorders. It has multiple approved products and several products in various stages of clinical development.

Location: King of Prussia, Pennsylvania United States

Year Established: 2005

Website: www.iceutica.com

Therapeutic Focus: Oncology, Pain, Musculo-Skeletal, Respiratory

Development Status: Phase 2

Corporate Partners: Iroko

Funds Raised: Not Disclosed

Presenter: Matt Callahan, CEO

IGXBio, Inc.

IGXBio is a clinical-stage company targeting infectious diseases. The company has an approved IND with the FDA for a Phase 1/2 clinical trial in HIV-infected patients.

Location: Lenexa, Kansas United States

Year Established: 2013

Website: www.igxbio.com

Therapeutic Focus: Infectious Diseases

Development Status: IGXBio

Corporate Partners: Seeking a corporate partner

Funds Raised: \$25+ M: \$21 M grants, \$4 M in local angel investor financing

Presenter: Jim Laufenberg, President & CEO

Imanova Ltd.

Imanova is a world-leading centre for imaging sciences and their high-value application to biomarker and early drug development.

Location: London, United Kingdom

Year Established: 2011

Website: www.imanova.co.uk

Therapeutic Focus: CNS, Oncology, Respiratory, Inflammation, Cardiovascular

Development Status: NA

Corporate Partners: NA

Funds Raised: NA

Presenter: Dr. Kevin Cox, CEO

Immunocore Limited

Immunocore is a clinical-stage company with a platform of bio-specific proteins that has partnerships with Genentech, GSK, Medimmune and Lilly. Its lead product is in Phase 2a trials in patients with metastatic melanoma.

Location: Abingdon, Oxfordshire United Kingdom

Year Established: 2008

Website: www.immunocore.com

Therapeutic Focus: Cancer Immunotherapy, Virology, Autoimmune Disease

Development Status: Phase 2a

Corporate Partners: Genentech, GlaxoSmithKline, Medimmune, Eli Lilly

Funds Raised: NA

Presenter: Eva-Lotta Allan, CBO

Immunome Inc.

Immunome is a discovery-stage company that is using an immunotherapy discovery engine to identify new cancer targets and therapies. The technology platform, co-invented by Robert Weinberg at MIT's Whitehead Institute, has enabled the company to simultaneously discover multiple cancer antigens paired with native human antibodies that attack cancer cells.

Location: Wynnwood, Pennsylvania United States

Year Established: 2009

Website: www.immunomeinc.com

Therapeutic Focus: Cancer Immunotherapy

Development Status: Discovery

Corporate Partners: NA

Funds Raised: \$3.7 M

Presenter: Jane H. Hollingsworth, Executive Chairman

Immunomic Therapeutics, Inc.

ITI is commercializing a vaccine development platform through the development of product candidates in various stages of clinical testing. It is focused on the treatment of allergic diseases.

Location: Hershey, Pennsylvania United States

Year Established: 2006

Website: www.immunomix.com

Therapeutic Focus: Allergy, Inflammation, Oncology

Development Status: Phase 2

Corporate Partners: Asterias (cancer vaccine), Major animal health company (animal health product), BioJect (delivery), Nature Technologies (DNA technology)

Funds Raised: \$15+ M since inception

Presenter: Dr. William Hearl, CEO

Immunovaccine Inc. (TSX.V: IMV)

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines. It has advanced two T cell activation therapies through Phase 1 human trials. It also has an infectious disease pipeline that includes a vaccine for respiratory syncytial virus and a collaboration with the NIH for vaccines for Ebola and anthrax.

Location: Halifax, Nova Scotia Canada

Year Established: 2000

Website: www.imvaccine.com

Therapeutic Focus: Cancer Immunotherapy, Infectious Diseases

Development Status: Phase 1/Phase 2 (oncology), preclinical (infectious disease)

Corporate Partners: NA

Funds Raised: NA

Presenter: Marc Mansour, PhD, MBA, CEO

Inovio Pharmaceuticals (NASDAQ: INO)

Inovio is a clinical-stage company that is developing immunotherapies that activate immune responses to prevent and treat disease that have shown clinically significant efficacy with a favorable safety profile.

Location: Plymouth Meeting, Pennsylvania United States

Year Established: 2000

Website: www.inovio.com

Therapeutic Focus: Oncology, Infectious Disease

Development Status: Phase 3

Corporate Partners: Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba

Funds Raised: \$160+ M raised since 2009

Presenter: J. Joseph Kim, PhD, President & CEO

Integene International, LLC

Integene is a preclinical company developing a platform for gene therapy to treat a broad range of vascular diseases including peripheral arterial disease, critical limb ischemia and coronary artery disease. The company is initially focusing on critical limb ischemia that may qualify for orphan drug designation.

Location: Miami, Florida United States

Year Established: 2010

Website: www.integene-int.com

Therapeutic Focus: Vascular Regeneration, Gene Therapy

Development Status: Preclinical proof-of-concept completed; Pre-IND being submitted to U.S. FDA; Human studies expected to start in 2015/2016

Corporate Partners: NA

Funds Raised: \$12 M in grant funding from NIH, AHA, others for preclinical work to date \$600K bridge financing in August 2014

Presenter: Jim DeMesa, MD, MBA, CEO

Intellia Therapeutics, Inc.

Intellia is a development-stage biotech company developing CRISPR/Cas9 gene editing technology that permits the editing of any gene in any organism with simplicity and flexibility. It has a broad IP portfolio covering the application of this technology for human therapeutic use.

Location: Cambridge, Massachusetts United States

Year Established: 2014

Website: www.intelliatx.com

Therapeutic Focus: Genome Engineering

Development Status: R&D

Corporate Partners: NA

Funds Raised: \$15 M Series A

Presenter: Nesson Bermingham, PhD, President & CEO

IntelliCyt Corporation

IntelliCyt is a commercial growth-stage life sciences tools company that develops systems that help researchers gain a better understanding of cells and their role in disease. Its instrumentation, software and reagent products are used by a wide range of life sciences organizations.

Location: Albuquerque, New Mexico United States

Year Established: 2007

Website: www.intellicyt.com

Therapeutic Focus: Drug Discovery, Immunology, Oncology

Development Status: Commercially released products, revenue growth stage

Corporate Partners: NA

Funds Raised: \$13.1 M to date

Presenter: R. Terry Dunlay, CEO

Intensity Therapeutics, Inc.

This specialty pharmaceutical company develops novel chemotherapeutic products that use advanced imaging, formulation science and immunology in what it calls in situ chemovaccination. It is a preclinical, development-stage company that has had a Type B pre-NDA meeting with the FDA.

Location: Westport, Connecticut United States

Year Established: 2012

Website: www.intensitytherapeutics.com

Therapeutic Focus: Oncology

Development Status: In process of filing IND for Phase 1

Corporate Partners: National Cancer Institute

Funds Raised: Nearly \$1.7 M

Presenter: Lewis H. Bender, Founder & CEO

International Stem Cell Corp. (OTCQB: ISCO)

ISCO is a California-based regenerative medicine company developing novel stem cell based therapies and biomedical products. ISCO's core technology can be used to create clinical-grade cells and tissue for allogeneic therapy that are histocompatible with hundreds of millions of people.

Location: Carlsbad, California United States

Year Established: 2007

Website: www.internationalstemcell.com

Therapeutic Focus: Neurology

Development Status: Phase 1

Corporate Partners: Duke, Sanford-Burham, Scripps

Funds Raised: More than \$70 M

Presenter: Simon Craw, PhD, Executive VP, Business Development

Intezyne, Inc.

Intezyne is a development-stage oncology company. Its lead asset is a small molecule with a new mechanism of action targeting down-regulation of GRP78, a major cancer cell resistance protein. GRP78 is preferentially expressed on the tumor cell surface, enabling specific tumor cell targeting and limiting the impact on healthy cells.

Location: Tampa, Florida United States

Year Established: 2004

Website: www.intezyne.com

Therapeutic Focus: Oncology

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: \$40 M

Presenter: Tim Coan, CFO

Invion Ltd. (ASX: IVX)

Invion is a clinical-stage life sciences company developing treatments for inflammatory diseases including asthma, COPD, cystic fibrosis and lupus. It has three drug candidates in development including two in Phase 2 trials, one to treat inflammatory airway diseases and one for the treatment of autoimmune diseases.

Location: Brisbane, Queensland Australia

Year Established: 2001

Website: www.inviongroup.com

Therapeutic Focus: Respiratory, Inflammatory Diseases

Development Status: INV102: Phase 2, INV103: Phase 2, INV104: Preclinical

Corporate Partners: NA

Funds Raised: NA

Presenter: Greg Collier, PhD, Managing Director and CEO

Isarna Therapeutics GmbH

Isarna develops TGF- β inhibitors to fight cancer and treat ophthalmic and fibrotic diseases. It is advancing a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes. Its most advanced lead compound will enter the clinic in 2015.

Location: Munich, Germany

Year Established: 2013

Website: www.isarna-therapeutics.com

Therapeutic Focus: Oncology, Ophthalmology, Fibrosis

Development Status: Preclinical; Phase 2 first generation asset being partnered

Corporate Partners: Roche/Santaris, Sanofi (CMO)

Funds Raised: NA

Presenter: Dr. Philippe Calais, CEO

JDP Therapeutics Inc.

JDP Therapeutics is a clinical Phase 3 stage specialty pharmaceutical company that develops small molecule therapeutics to treat acute allergic reactions, primarily in a hospital setting. Its lead product has completed its first Phase 3 clinical study.

Location: Blue Bell, Pennsylvania United States

Year Established: 2009

Website: www.jdptherapeutics.com

Therapeutic Focus: Allergy, Acute Allergic Reactions

Development Status: Phase 3

Corporate Partners: Algorithm Pharma, Jubilant HollisterStier

Funds Raised: NA

Presenter: Jie Du, PhD, President & CEO

Juventas Therapeutics, Inc.

Juventas develops biopharmaceuticals that activate the body's natural regenerative repair processes. Its factor-based therapeutic approach provides an alternative to cellular therapy platforms. The company's lead product is currently in Phase 2 clinical trials for heart failure and limb ischemia.

Location: Cleveland, Ohio United States

Year Established: 2007

Website: www.juventasinc.com

Therapeutic Focus: Cardiovascular

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: \$38 M to date in venture capital and grants

Presenter: Rahul Aras, PhD, President & CEO

Kalos Therapeutics, Inc.

Kalos is a preclinical-stage focused on hyperproliferative disorders targeting cancer and age-related macular degeneration. It aims to translate the natural hemodynamic controls and antiproliferative activities of the ANO family of peptides into therapies.

Location: San Diego, California United States

Year Established: 2005

Website: www.kalostpx.com

Therapeutic Focus: Oncology, Ascites, Wet Macular Degeneration, Animal Health

Development Status: IND Enabling work

Corporate Partners: Covidien Mallinckrodt

Funds Raised: \$2.1 M

Presenter: George Colberg, Co-Founder & CEO

Karus Therapeutics Ltd.

Karus Therapeutics is a preclinical-stage company developing medicines for the treatment of inflammatory disease and cancers. It has developed small molecule drugs from its isoform-selective P13K and HDAC6 inhibitor programs.

Location: Abingdon, Oxfordshire United Kingdom

Year Established: 2006

Website: www.karustherapeutics.com

Therapeutic Focus: Inflammation, Oncology

Development Status: IND/CRA studies - Phase 1 expected 1H15

Corporate Partners: NA

Funds Raised: \$28+ M to date; further tranche of Series B funding committed

Presenter: Simon Kerry, PhD MBA, CEO

Kesios Therapeutics Limited

Kesios is a preclinical oncology company with a lead compound that should be ready for a Phase 1 POC trial in oncology by the middle of 2015.

Location: London, United Kingdom

Year Established: 2012

Website: www.kesios.com

Therapeutic Focus: Oncology

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: £1.85 M

Presenter: Alain Maiore, CEO

Kineta, Inc.

Kineta develops therapies through the end of Phase 1 and then licenses the drug to pharma on a global or regional basis. It is developing five drug programs with a focus on innate immunity and its role in autoimmune (Phase 1) and infectious disease (IND) and non-narcotic chronic pain (pre-IND).

Location: Seattle, Washington United States

Year Established: 2008

Website: kinetabio.com

Therapeutic Focus: Autoimmune Diseases (PsO, PsA, lupus, MS), Innate Immune Antivirals, Non-Narcotic Chronic Pain

Development Status: Phase 1 (autoimmune disease), IND stage (Innate immune antiviral and chronic pain)

Corporate Partners: MPI Research, Chimera Biotec, Medical Marketing Economics, Life Chemicals

Funds Raised: \$40+ M, grants and contracts; \$35+ M in equity

Presenter: Charles Magness, PhD, Co-founder & CEO

Kuros Biosurgery AG

Kuros Biosurgery is a clinical-stage company developing a dural sealant product and orthobiologics products that are ready for Phase 3 and Phase 2 in trauma and spinal indications, respectively.

Location: Zurich, Switzerland

Year Established: 2002

Website: www.kuros.ch

Therapeutic Focus: Orthobiologic, Sealants, Surgical Wounds

Development Status: Clinical-stage

Corporate Partners: NA

Funds Raised: >\$200 M, of which approx. \$30 M is equity financing

Presenter: Didier Cowling, CEO

Lion Biotechnologies, Inc. (OTCBB: LBIO)

This cancer immunotherapy company is developing an adoptive cell therapy with T lymphocytes derived from patient's tumor or tumor-infiltrating lymphocytes. The company anticipates initiating a Phase 2 clinical trial in 2015.

Location: Woodland Hills, California United States

Year Established: 2013

Website: www.lionbio.com

Therapeutic Focus: Oncology

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: \$23 M raised in 2013

Presenter: Elma Hawkins, PhD, President & COO

Luoxis Diagnostics, Inc.

Luoxis is a diagnostic company developing a technology to measure redox potential, also called oxidation-reduction potential or ORP. Redox potential has been implicated in numerous critical injuries, illnesses and chronic conditions. Its product is approved for marketing in the EU and Canada.

Location: Englewood, Colorado United States

Year Established: 2013

Website: www.luoxis.com

Therapeutic Focus: Oxidative Stress, Critical Care Medicine, Trauma, Emergency Medicine

Development Status: CE Marked, Health Canada approved, FDA clinical studies under way

Corporate Partners: Active discussions with corporate partners; Luoxis is a subsidiary of Ampio Pharmaceuticals, Inc.

Funds Raised: \$5 M raised in a private placement in May 2013

Presenter: Josh Disbrow, President & CEO

Lysosomal Therapeutics Inc.

Lysosomal Therapeutics is a discovery-stage company that leverages lysosomal biology to develop small molecules for the treatment of neurodegenerative disease. Its lead program focuses on Gaucher's and Parkinson's disease and is in lead optimization.

Location: Cambridge, Massachusetts United States

Year Established: 2012

Website: www.lysosomaltx.com

Therapeutic Focus: Lysosomal Storage Disease, Neurodegenerative Disease

Development Status: Lead program is in lead optimization

Corporate Partners: NA

Funds Raised: \$4.8M seed round to fund the hit-to-lead stage

Presenter: Kees Been, PhD, President & CEO

MabVax Therapeutics Holdings (OTCQB: MBVX)

MabVax is a clinical-stage biotechnology company that is integrating human antibody discovery technology with multiple therapeutic cancer vaccines. It has two vaccines in late Phase 2 clinical trials for ovarian cancer and sarcoma. Its lead antibody should enter the clinic by midyear for pancreatic cancer.

Location: San Diego, California United States

Year Established: 2008

Website: www.mabvax.com

Therapeutic Focus: Oncology, Cancer Immunotherapy

Development Status: Sarcoma vaccine Phase 2b; Ovarian vaccine Phase 2b; Neuroblastoma vaccine Phase 2b; HuMab 5B1 Phase 1a as PET diagnostic and therapeutic agent

Corporate Partners: Memorial Sloan-Kettering Cancer Center, Patheon Biologics, Heidelberg Pharma

Funds Raised: \$22 M: \$18 M from investors, \$6 M from the NIH

Presenter: David Hansen, Co-Founder, President & CEO

Mast Therapeutics, Inc. (NYSE MKT: MSTX)

Mast Therapeutics is a clinical-stage company focused on hematology. Its lead product, currently in a pivotal Phase 3 study, is the most clinically-advanced drug in development for sickle cell patients. It also has drugs in Phase 2 products for acute limb ischemia and acute decompensated heart failure.

Location: San Diego, California United States

Year Established: 1995

Website: www.masttherapeutics.com

Therapeutic Focus: Hematology

Development Status: Sickle Cell Disease: Phase 3; Acute Limb Ischemia: Phase 2; Acute Decompensated Heart Failure: Phase 2

Corporate Partners: NA

Funds Raised: NA

Presenter: Brian M. Culley, CEO

Matinas BioPharma Holdings (OTCQB: MTNB)

Matinas is a development-stage biopharmaceutical company identifying and developing drugs to treat blood lipid abnormalities and cardiovascular and metabolic diseases. Its lead product is designed and formulated for applications in dyslipidemia and the company expects to initiate Phase 3 registration in 2015.

Location: Bedminster, New Jersey United States

Year Established: 2011

Website: www.matinasbiopharma.com

Therapeutic Focus: Dyslipidemia, Cardiovascular Disease

Development Status: Filed IND for MAT9001 in October 2014; initiating Phase 3 2015; First-in-human PK/PD study Nov. 2014, results expected 2Q15

Corporate Partners: NA

Funds Raised: Closed \$15 M Private Placement Aug. 12, 2013; total of \$16 M to date

Presenter: Roelof Rongen, President & CEO

MaxCyte, Inc.

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Using a scalable electroporation process, MaxCyte's proprietary cell transfection platform is used by pharmaceutical and biotechnology companies around the world to engineer cells for a wide range of applications.

Location: Gaithersburg, Maryland United States

Year Established: 1999

Website: www.maxcyte.com

Therapeutic Focus: Oncology

Development Status: Phase 1

Corporate Partners: NA

Funds Raised: NA

Presenter: Douglas Doerfler, Founding President & CEO

Medgenics, Inc. (NYSE MKT: MDCN)

Medgenics is a clinical-stage company developing an ex vivo gene therapy platform for the treatment of rare and orphan diseases including renal anemia, beta thalassemia, MDS and short bowel syndrome. Its lead product is in Phase 2 clinical trials.

Location: Wayne, Pennsylvania United States

Year Established: 2002

Website: www.medgenics.com

Therapeutic Focus: Renal Anemia, Beta Thalassemia, MDS, Rare and Orphan Diseases, Short Bowel Syndrome

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: \$24 M raised Nov. 2014

Presenter: Mike Cola, CEO

Medicenna Therapeutics, Inc

Medicenna is a clinical-stage oncology company with a lead product entering Phase 2b trials for recurrent glioblastoma following compelling efficacy over existing standard of care.

Location: Vancouver, British Columbia Canada

Year Established: 2012

Website: www.medicenna.com

Therapeutic Focus: Oncology

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: NA

Presenter: Fahar Merchant, President & CEO

Medigene AG (FRANKFURT: MDGI)

Medigene is a commercial-stage biotechnology company focused on the development of personalized T cell immunotherapies, particularly those related to haematological malignancies. It has one approved drug on the market, Veregen, and several programs in development for the treatment of various cancers.

Location: Munich (Planegg/Martinsried), Bavaria Germany

Year Established: 1994

Website: www.medigene.com

Therapeutic Focus: Oncology, Immunotherapy

Development Status: DC Vaccine: Phase 2; T-cell receptor; modified T cells: pre-clinical; Anti-TCR monoclonal antibodies: Discovery; AAVLP technology: Preclinical; EndoTag-1: Phase 2; RhuDex: Phase 2; AAV Library: in development

Corporate Partners: Veregen: worldwide partners; EndoTAG-1: SynCore Biotechnology Co. Ltd.; RhuDex: Dr. Falk Pharma GmbH

Funds Raised: €15.9 M (2014)

Presenter: Prof. Dolores J. Schendel, CSO

MedVax Technologies, Inc.

MedVax is a clinical-stage biopharmaceutical company developing cancer vaccines. Its two lead products are focused on antigen presenting cells of the immune system. One has completed Phase 2a clinical trials in small cell lung cancer and the other is completing a second Phase 1 study in solid tumors.

Location: Miami, Florida United States

Year Established: 2012

Website: www.medvax.net

Therapeutic Focus: Oncology

Development Status: Clinical-stage

Corporate Partners: NA

Funds Raised: NA

Presenter: Robert K. Brooks, JD, Chairman & CEO

Midatech Pharma PLC (LSE AIM: MTPH)

Midatech is an acquisitive clinical-stage specialty pharma company focused on endocrinology, diabetes, neurology and ophthalmology. Its lead product is in Phase 2 clinical trials.

Location: Abingdon, United Kingdom

Year Established: 2004

Website: www.midatechpharma.com

Therapeutic Focus: Endocrinology, Diabetes, Neurology & Ophthalmology

Development Status: Phase 2

Corporate Partners: Two top 10 Pharma & two specialty pharma companies

Funds Raised: \$51 M at IPO Dec. 2014, prior to IPO \$70 M

Presenter: Jim Phillips MD, MBA, CEO

Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals is a clinical-stage company that develops small molecule therapeutics for transient cardiovascular conditions. Its lead product is a treatment of paroxysmal supraventricular tachycardia that allows patients to self-administer at the onset of symptoms. It will begin Phase 2 studies in 2015.

Location: Montreal, Quebec Canada

Year Established: 2005

Website: www.milestonepharma.com

Therapeutic Focus: Cardiology

Development Status: Phase 2a

Corporate Partners: NA

Funds Raised: \$17 M to date

Presenter: Philippe Douville, PhD, MBA, President & CEO

MiNA Therapeutics Limited

MiNA Therapeutics is a preclinical-stage oncology company working on a class of medicines that selectively up-regulate proteins inside patient cells. Its RNA activation platform enables up-regulation of beneficial proteins by selective and long-lasting transcriptional activation of a target gene.

Location: London, United Kingdom

Year Established: 2008

Website: www.minatx.com

Therapeutic Focus: Oncology

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: \$2 M raised to date

Presenter: Robert Habib, CEO

MTG Biotherapeutics LLC

MTG Biotherapeutics is seeking investment partners for the development and commercialization of MTG-201, a first-in-class anti-cancer viral protein delivery therapy that treats cancer by a dual mechanism. MTG-201 represents the first clinical approach to treating cancer based on REIC deficiency with significant IP to 2035.

Location: San Diego, California United States

Year Established: 2014

Website: www.mtg-bio.com

Therapeutic Focus: Oncology

Development Status: Phase 2 Prostate; Phase 1 Mesothelioma

Corporate Partners: Momotaro-Gene Corp., Kyorin Pharmaceuticals (Japan)

Funds Raised: Approx. \$20 M, no prior dilution or US fundraising. Will be a Series A funding with no prior dilution

Presenter: Richard Lowenthal, MSc, MBA, President & CEO

Multimeric Biotherapeutics, Inc.

This early clinical-stage immune-oncology company is using a ligand based technology platform to develop immune-oncology products and vaccines. Its lead products target ovarian and prostate cancers.

Location: La Jolla, California United States

Year Established: 2008

Website: www.multimericbio.com

Therapeutic Focus: Immuno-Oncology, Vaccines

Development Status: Preclinical and Phase I

Corporate Partners: NA

Funds Raised: >\$1 M in NIH grants, \$250 in angel funding

Presenter: Richard Kornbluth, MD, PhD, President & CSO

NanoViricides, Inc. (NYSE MKT: NNVC)

NanoViricides is a preclinical nanobiotech company with a platform technology to rapidly create new targeting anti-virals. Human trials are planned in 2015 for Ebola and FluCide™ (complicated influenza in hospitalized patients).

Location: West Haven, Connecticut United States

Year Established: 2005

Website: www.nanoviricides.com

Therapeutic Focus: Anti-Virals

Development Status: Preclinical, preparing for human trials 1Q15 for Ebola

Corporate Partners: NA

Funds Raised: \$85 M

Presenter: Eugene Seymour, MD, MPH, CEO

Navidea Biopharmaceuticals (NYSE MKT: NAVB)

Navidea is a commercial-stage company that develops diagnostic and therapeutic radiopharmaceuticals. Its first product has US and European approval and is used to determine the spread of cancer. The company also plans to apply its core molecule to therapeutics for arthritis, cancer and infectious diseases.

Location: Dublin, Ohio United States

Year Established: 1983

Website: www.navidea.com

Therapeutic Focus: Oncology, Inflammation, Infectious Disease, Neurology

Development Status: Lymphoseek® Injection, Marketed; Manocept platform (RA, KS others); NAV4694, Phase 3(AD); Phase 2 (MCI); NAV5001, Phase 3(PD) Phase 2(DLB)

Corporate Partners: Cardinal Health; Multiple International partnerships; Essex Woodlands Rheumco; manufacturing: Siemens PETNET; Nordion

Funds Raised: NA

Presenter: Rick Gonzalez, CEO

NeoStem, Inc. (NASDAQ: NBS)

NeoStem is a clinical-stage cellular therapy company pursuing the development of proprietary cell therapy products as well as a revenue-generating contract development and manufacturing services business. Its lead product is ready for Phase 3 development and it has two additional Phase 2-ready programs.

Location: New York, New York United States

Year Established: 2006

Website: www.neostem.com

Therapeutic Focus: Cancer Immunotherapy, Ischemic Repair, Immune Modulation, Tissue Regeneration

Development Status: NBS20: Phase 3 ready; NBS10: Phase 2; NBS03: Phase 2 ready

Corporate Partners: NA

Funds Raised: NA

Presenter: Dr. Robin L Smith, Chairman & CEO

NetBio, Inc.

NetBio is commercializing products and services in the field of Rapid DNA Analysis. RDNA is performed in the field at police stations, embassies, borders and ports by non-technical users when timely DNA information is needed.

Location: Waltham, Massachusetts United States

Year Established: 2000

Website: www.netbio.com

Therapeutic Focus: Human Forensic Identification; POC Nucleic Acid-Based Diagnostics

Development Status: Marketed

Corporate Partners: GE (exclusive worldwide rights: police, criminal forensic labs)

Funds Raised: \$100+ M in non-dilutive financing

Presenter: Richard Selden, MD, PhD, Executive Chairman & CEO

Neuralstem, Inc. (NYSE MKT: CUR)

Neuralstem is a dual-focused, cell therapy/small molecule platform technology company developing CNS therapies using regionally specific human neural stem cells. The company possesses a strong patent portfolio & extensive pipeline.

Location: Germantown, Maryland United States

Year Established: 1996

Website: www.neuralstem.com

Therapeutic Focus: CNS

Development Status: Phase 2, Phase 1, Preclinical

Corporate Partners: NIH and ALSA grants for ALS clinical trials; NIH and DOD grants for MDD

Funds Raised: ~\$120 M

Presenter: Richard Garr, JD, President & CEO

NeuroMetrix, Inc. (NASDAQ: NURO)

NeuroMetrix develops wearable medical technology and point-of-care tests to help patients and physicians better manage chronic pain, nerve diseases and sleep disorders. It has FDA-cleared prescription and OTC products and focuses on diabetic neuropathies.

Location: Waltham, Massachusetts United States

Year Established: 1996

Website: www.NeuroMetrix.com

Therapeutic Focus: Neuropathic Pain, Diabetic Neuropathy

Development Status: FDA approved, marketed diagnostic and therapeutic products

Corporate Partners: Omron Healthcare, DJO Global

Funds Raised: > \$100 M

Presenter: Shai N. Gozani MD, PhD, Chairman, President & CEO

Neurotrope, Inc. (OTCQB: NTRP)

Neurotrope is developing therapeutics for neurodegenerative diseases such as Alzheimer's disease and orphan drug indications including Niemann Pick Type C and Fragile X Syndrome. The company's lead compound is currently initiating a Phase 2a clinical trial for the treatment of AD. It is also developing a simple AD diagnostic test.

Location: Newark, New Jersey United States

Year Established: 2012

Website: www.neurotropebioscience.com

Therapeutic Focus: Neurodegenerative Diseases

Development Status: Phase 2a

Corporate Partners: Blanchette Rockefeller Neurosciences Institute

Funds Raised: \$23 M of convertible preferred stock

Presenter: Charles S. Ramat, President & CEO

Nexstim Plc (NASDAQ Helsinki: NXTMH)

Nexstim is a medical technology company aimed at improving rehabilitation for stroke patients with noninvasive neurostimulation. It has a marketed diagnostic, an FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation device.

Location: Helsinki, Finland

Year Established: 2000

Website: www.nexstim.com

Therapeutic Focus: Stroke

Development Status: Marketed in Europe and USA, Therapy Phase 3 trials

Corporate Partners: NA

Funds Raised: Pre-IPO financing rounds of €35 M and IPO €15 M, total: €50 M

Presenter: Janne Huhtala, CEO

Nordic Nanovector ASA (NOTC: NANO)

This clinical-stage company develops radioimmunotherapeutics for the treatment of severe cancers. Its lead product candidate is currently undergoing a Phase 1/2 clinical trial for the treatment of patients with non-Hodgkin Lymphoma.

Location: Oslo, Norway

Year Established: 2009

Website: www.nordicnanovector.com

Therapeutic Focus: Oncology, Hematology

Development Status: Phase 1/2

Corporate Partners: NA

Funds Raised: \$60+ M with approx. \$40 M raised July 2014

Presenter: Luigi Costa, CEO

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)

Northwest Biotherapeutics is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, without the side effects of chemotherapy drugs. The company has a broad platform technology for DCVax dendritic cell-based vaccines.

Location: Bethesda, Maryland United States

Year Established: 1996

Website: www.nwbio.com

Therapeutic Focus: Cancer Immunotherapy

Development Status: DCVax-L: Phase 3; DCVax-Direct, 60-patient Phase 1/2 trial

Corporate Partners: Cognate Bioservices

Funds Raised: NA

Presenter: Linda F. Powers, Chairman & CEO

Nuvo Research Inc. (TSX: NRI)

Nuvo Research is a specialty pharmaceutical company with a diverse portfolio of products and technologies. It operates two business units, one devoted to topical products and technologies and another devoted to immunology. It has four FDA approved products and its lead product for allergic rhinitis is in Phase 2.

Location: Mississauga, Ontario Canada

Year Established: 1990

Website: www.nuvoresearch.com

Therapeutic Focus: Refractory Allergic Rhinitis

Development Status: WF10 in Phase 2; Four FDA-approved products

Corporate Partners: Horizon Pharma; Paladin; Vianex; Italchimici; NovaMedica; Galderma; Galen; Eurocept; Ranbaxy; Vargas Laboratorios; Elder; NeoPharm

Funds Raised: CAD \$190+ M

Presenter: John London, President & Co, CEO

Omni Bio Pharmaceutical, Inc. (OTCBB: OMBP)

Omni Bio is an emerging biotech company aiming to revolutionize the way immune-mediated inflammatory diseases are treated. Its target indications include Type 1 diabetes, graft vs host disease, chronic gout as well as other inflammatory conditions.

Location: Fort Collins, Colorado United States

Year Established: 2006

Website: www.omnibiopharma.com

Therapeutic Focus: Immune-Mediated Inflammatory Diseases

Development Status: Preclinical

Corporate Partners: Gallus BioPharmaceuticals

Funds Raised: Approx. \$12 M since going public in 2009

Presenter: Bruce Schneider, PhD, CEO

OncoSec Medical Inc. (OTCQB: ONCS)

OncoSec Medical is a clinical-stage company developing cancer immunotherapies. Its core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based immune-targeted agents. Its lead product is in Phase 2b clinical trials.

Location: San Diego, California United States

Year Established:

Website: www.oncosec.com

Therapeutic Focus: Immunotherapy, Oncology, Gene Therapy

Development Status: Phase 2B

Corporate Partners: Merck, Plexxicon, PerkinElmer

Funds Raised: NA

Presenter: Punit Dhillon, CEO

OncoTab, Inc.

OncoTab develops and commercializes products that span the lifecycle of cancer. It has a worldwide exclusive license to a patented technology platform that has demonstrated diagnostic and therapeutic potential.

Location: Charlotte, North Carolina United States

Year Established: 2011

Website: www.oncotab.com

Therapeutic Focus: Oncology

Development Status: Studies for diagnostic approval; Preclinical Therapeutic Studies

Corporate Partners: NA

Funds Raised: \$1.8 M

Presenter: Pinku Mukherjee, PhD, President & CEO

ONXEO SA (EURONEXT: ONXEO)

ONXEO is a commercial stage biotech focused on orphan oncology diseases. It has three products in advanced clinical development with potential applications for liver cancer, oral mucositis and PTCL. It already has three products approved in either Europe or the US.

Location: Paris, France

Year Established: 2014

Website: www.onxeo.com

Therapeutic Focus: Orphan Oncology

Development Status: Phase 2 completed, Phase 3, Marketed

Corporate Partners: NA

Funds Raised: NA

Presenter: Judith Greciet, CEO

Opsona Therapeutics Ltd.

Opsona Therapeutics is a clinical-stage immunology drug development company focused on developing therapeutic approaches to key targets of the innate immune system associated with a wide range of human disease including autoimmune and inflammatory disease with a specific focus on solid organ transplantation and oncology.

Location: Dublin, Ireland

Year Established: 2004

Website: www.opsona.com

Therapeutic Focus: Inflammation, Oncology

Development Status: Phase 2 clinical study

Corporate Partners: NA

Funds Raised: \$90 M

Presenter: Martin Welschof, PhD, CEO

ORIG3N, Inc.

ORIG3N is a preclinical-stage biotech company that is developing treatments for rare genetically inherited disease based on cellular reprogramming technology. It currently markets a direct-to-consumer bio-repository.

Location: Boston, Massachusetts United States

Year Established: 2014

Website: www.orig3n.com

Therapeutic Focus: Rare Genetically Inherited Diseases

Development Status: NA

Corporate Partners: NA

Funds Raised: Self-funded; currently raising \$2 M - \$5 M

Presenter: Robin Y. Smith, CEO

ORYX GmbH & Co. KG

ORYX develops promising cancer projects from research institutions and development through preclinical and clinical Phases until proof of concept/efficacy. It oversees a product portfolio of three projects currently in Phase 1/2a clinical trials.

Location: Baldham/Munich, Bavaria Germany

Year Established: 2007

Website: www.oryx-medicine.com

Therapeutic Focus: Oncology

Development Status: Phase 1/2a

Corporate Partners: Partnering after successful proof-of-concept in man.

Funds Raised: €25 M to date, private investors

Presenter: Dr. Bernard Huber, CEO & Founder

Oxford BioMedica Plc (LSE: OXB)

Oxford BioMedica is a clinical-stage gene and cell therapy company targeting markets in ophthalmology, CNS and oncology. It has contracts with Novartis covering license to its IP and vector manufacture of its lead product.

Location: Oxford, Oxfordshire United Kingdom

Year Established: 1996

Website: www.oxfordbiomedica.co.uk

Therapeutic Focus: Ophthalmology, CNS, Oncology

Development Status: Preclinical / Phase 1/2

Corporate Partners: IP and product licenses granted to Novartis, GSK and Sanofi

Funds Raised: £170 M raised since inception

Presenter: John Dawson, CEO

Parnell Pharmaceuticals Holdings (NASDAQ: PARN)

Parnell is a commercial-stage animal pharmaceutical company with operations in drug development, manufacturing and commercialization. It has marketed products for cattle fertility and osteoarthritis in dogs and horses. It is developing new products for companion animals in osteoarthritis, dermatology, orthopedics, anesthetics and metabolic diseases.

Location: Overland Park, Kansas United States

Year Established: 1986

Website: www.parnell.com

Therapeutic Focus: Veterinary

Development Status: Marketed, Phase 3, Phase 1a

Corporate Partners: Lonza, Bayer, Eli Lilly

Funds Raised: Pre-IPO: \$35+ M; IPO: \$50 M

Presenter: Robert Joseph, BSc, BBus, BCom, CPA, President & CEO

PathoQuest SAS

PathoQuest is a spin-out of the Institut Pasteur that is developing molecular diagnostics in the area of infectious disease that combine Whole Genome NGS and Cloud computing-based software as a service. It is completing a clinical study and plans a clinical trial in the US in early 2015.

Location: Paris, France

Year Established: 2010

Website: www.pathoquest.com

Therapeutic Focus: Infectious Diseases

Development Status: Clinic

Corporate Partners: NA

Funds Raised: €6.6 M since March 2011

Presenter: Luc Boblet, PhD, CEO

PCI Biotech AS (OSE Axxess: PCIB)

PCI Biotech is a clinical-stage company developing anti-cancer products and a CTL-inducer for therapeutic vaccination using its endosomal escape technology platform. The company targets head and neck and bile duct cancers by triggering endosomal escape of established anticancer agents.

Location: Lysaker, Norway

Year Established: 2000

Website: www.pcibiotech.com

Therapeutic Focus: Oncology, Therapeutic Vaccination

Development Status: Clinical-stage, Phase 2

Corporate Partners: NA

Funds Raised: NOK 60 M at IPO 2008; NOK 90 M rights issue 2010; NOK 50 M non-dilutive funding 2008-2014

Presenter: Dr. Per Walday, PhD, CEO

Pediatric Bioscience, Inc.

This diagnostic company has developed a novel blood biomarker test for the largest known subtype of autism. The test will allow for earlier diagnosis and treatment of this specific form of autism. The company will make the test available in the fall of 2015 through its CLIA laboratory service model.

Location: San Diego, California United States

Year Established: 2006

Website: www.pedbio.com

Therapeutic Focus: Autism, Developmental Delay, Neurological Disorders

Development Status: Pre-market, launch is planned for 3Q15

Corporate Partners: Pacific Child & Family Services, MIND Institute at UC Davis

Funds Raised: \$1.2 M Series A (2010); \$1.3 M Series B (2014), \$700 K+ Convertible Bridge (2014)

Presenter: Jan D'Alvise, President & CEO

Phylogica Ltd. (ASX: PYC)

Phylogica is a discovery-stage company that owns a therapeutic class of peptides. It has entered into five discovery collaborations with large pharmaceutical companies. It has also recently launched a program to develop drugs against breast cancer.

Location: Subiaco/Perth Western Australia

Year Established: 2005

Website: www.phylogica.com

Therapeutic Focus: Oncology, Peptide Therapeutics

Development Status: Drug Discovery, preclinical

Corporate Partners: Genentech

Funds Raised: AUD \$40 M incl. \$6.1 M, Jan. 2014; \$6 M since 2010; \$6 M in non-dilutive grant funding

Presenter: Dr. Richard Hopkins, CEO

PixarBio Corporation

PixarBio, co-founded by Dr. Robert S. Langer of MIT and CEO Frank Reynolds, is a preclinical company that is researching and developing biomaterials to be used in combination with therapeutic agents to treat acute and chronic pain, spinal cord injury, epilepsy and Parkinson's disease.

Location: Cambridge, Massachusetts United States

Year Established: 2013

Website: www.pixarbio.com

Therapeutic Focus: Neurology

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: \$3 M+

Presenter: Frank Reynolds, Chairman & CEO

Polynoma LLC

Polynoma is a clinical-stage immuno-oncology company currently developing a therapeutic vaccine for the treatment of melanoma. It has commenced a Phase 3 clinical trial for its polyvalent antigen vaccine that contains multiple antigens that are shed from human melanoma cell lines.

Location: San Diego, California United States

Year Established: 2007

Website: www.polynoma.com

Therapeutic Focus: Immuno-Oncology, Melanoma

Development Status: Phase 3

Corporate Partners: Seeking corporate partners

Funds Raised: \$35+ M, grant funding; \$60+ M equity funding

Presenter: Andrew Buckland, CFO

Pre Diagnostics AS

This preclinical company is developing a blood-based test for Alzheimer's disease and pre-dementia. Amyloid plaque formations in AD can be monitored in blood macrophages where impeded beta-Amyloid-degradation signals disease onset. A new assay was successfully applied identifying pre-dementia clinical samples.

Location: Oslo, Norway

Year Established: 2013

Website: www.pre-diagnostics.com

Therapeutic Focus: Neurology, Alzheimer's Disease

Development Status: Prototype developed and proof of concept established with clinical samples

Corporate Partners: Furst Medical Laboratory, Akershus University Hospital

Funds Raised: Initial USD \$250 K + \$1.5 M soft funding, currently performing a \$1.6 M share issue

Presenter: Frank Swenson, PhD, CSO & Business Development (Americas)

Prevacus, Inc.

Prevacus is a preclinical-stage drug development company with a lead candidate that is a neurosteroid designed for nasal delivery following acute concussion for up to 14 days. It is currently completing IND enabling studies.

Location: Tallahassee, Florida United States

Year Established: 2012

Website: www.prevacus.com

Therapeutic Focus: Traumatic Brain Injury

Development Status: NA

Corporate Partners: NA

Funds Raised: \$500,000 first 6 months (2012). \$3 M (2013) Founder's round; start Series A Preferred \$1.2 M (2014)

Presenter: Jacob W. VanLandingham, PhD, Founder & President

Prokarium Ltd.

Prokarium is a clinical-stage vaccine company with a dual diarrhea and typhoid vaccine in Phase I clinical development and clostridium difficile and chlamydia vaccines in pre-clinical development. Its oral delivery platform can deliver any protein vaccine orally reducing cost and increasing stability.

Location: London, United Kingdom

Year Established: 2012

Website: www.prokarium.com

Therapeutic Focus: Infectious Diseases

Development Status: Phase 1a, Phase 2b

Corporate Partners: Flerie Invest AB (sole investor), undisclosed big pharma (research collaboration)

Funds Raised: \$5+ M, with \$3.5 M in 2014

Presenter: Ted Fjallman, PhD, CEO

Promentis Pharmaceuticals, Inc.

Promentis is a discovery-stage pharmaceutical company that is developing molecules for a variety of central nervous system disorders including schizophrenia, Parkinson's disease and pediatric disorders including autism.

Location: Milwaukee, Wisconsin United States

Year Established: 2008

Website: www.promentispharma.com

Therapeutic Focus: CNS

Development Status: Pre-IND

Corporate Partners: NA

Funds Raised: \$5+ M equity investment; \$3 M in grants (NIMH, Michael J. Fox Foundation)

Presenter: Chad E. Beyer, PhD, MBA, President & CEO

ProMetic Life Sciences Inc. (TSX: PLI)

This clinical-stage company specializes in bioseparations, plasma-derived therapeutics and small molecule development. It provides technologies for large-scale purification of biologics, drug development and the elimination of pathogens. It also uses its platform for internal discovery projects.

Location: Laval, Quebec Canada

Year Established: 1994

Website: www.prometic.com

Therapeutic Focus: Purification of Therapeutic Proteins, Fibrosis and Nephropathies

Development Status: Clinic

Corporate Partners: NA

Funds Raised: CAD \$500+ M in equity and partnerships

Presenter: Pierre Laurin, President & CEO

Protagen AG

Protagen is a commercial stage diagnostic company that uses a personalized medicine approach to enable differential diagnosis and patient stratification for RA, Systemic Lupus Erythematosus, MS and other diseases.

Location: Dortmund, North-Rhine-Westfalia Germany

Year Established: 1997

Website: www.protagen.com

Therapeutic Focus: Rheumatoid Arthritis; Systemic Sclerosis; Systemic Lupus Erythematosus; Multiple Sclerosis; Neuromyelitis Optica; Ankylosing Spondylitis

Development Status: Marketed

Corporate Partners: Pfizer

Funds Raised: NA

Presenter: Dr. Stefan Müllner, Chairman & CEO

Protagonist Therapeutics Inc.

Protagonist is a preclinical-stage company discovering and developing orally stable peptides based on NCEs against validated inflammatory targets and GI diseases. It identified its first development candidate in 2014.

Location: Milpitas, California United States

Year Established: 2009

Website: www.protagonist-inc.com

Therapeutic Focus: Inflammation, GI Disease

Development Status: Candidate nominated for oral alfa4beta7 peptide antagonist, 2014

Corporate Partners: Ironwood Pharmaceuticals (IRWD), Boston, USA; Zealand Pharma (ZEAL:CO), Copenhagen, Denmark

Funds Raised: \$27 M through Series B round in 2013 and Series A in 2009; \$15 M raised in non-dilutive financing through collaborations and research grants.

Presenter: Dinesh V. Patel, PhD, President & CEO

Protea Biosciences Group, Inc. (OTCQB: PRGB)

Protea Biosciences is a molecular information company providing solutions to the biopharmaceutical and life science industries. “Molecular information” refers to the generation and bioinformatic processing of very large data sets, obtained by applying the company’s technology to identify and characterize the proteins, metabolites, lipids and other biomolecules.

Location: Morgantown, West Virginia United States

Year Established: 2012

Website: www.proteabio.com

Therapeutic Focus: Mass Spectrometry Imaging; Biomarker Discovery

Development Status: Commercial

Corporate Partners: Memorial Sloan Kettering and Dana Farber Cancer Institute, University of Southampton (UK), InSphero AG

Funds Raised: \$60+ M to date

Presenter: Stephen Turner, Chairman & CEO

ProteoTech, Inc.

ProteoTech develops small molecule drugs for rare orphan amyloid diseases and disorders involving misfolded proteins. Its lead product candidate is entering a Phase 1/2 clinical trial for AL (immunoglobulin light chain) amyloidosis, multiple system atrophy and progressive supranuclear palsy.

Location: Kirkland, Washington United States

Year Established: 1996

Website: www.proteotech.com

Therapeutic Focus: Rare orphan Amyloid Diseases of Oncology, CNS (Parkinson’s and Alzheimer’s)

Development Status: Phase 1/2, preclinical

Corporate Partners: NA

Funds Raised: NA

Presenter: Roger Flugel, PhD, CEO

Pulmokine Inc.

Pulmokine is a early-clinical-stage company that is developing an inhaled PDGF receptor inhibitor for the treatment of pulmonary arterial hypertension, an orphan disease. The company has raised \$7 million in non-dilutive funding from the NHLBI to carry its program through a Phase 1 clinical trial.

Location: Rensselaer, New York United States

Year Established: 2007

Website: www.pulmokine.net

Therapeutic Focus: Pulmonary Arterial Hypertension

Development Status: IND/Phase 1

Corporate Partners: Gilead

Funds Raised: 7.5M non-dilutive funding from NIH

Presenter: Lawrence S. Zisman, MD, FACC, CEO

PxRadia Inc.

PxRadia, Inc. develops a humanized monoclonal antibody 2A2 for mitigating radiation toxicity and preventing cell death.

Location: Savannah, Georgia United States

Year Established: 2010

Website: www.pxradia.com

Therapeutic Focus: Gastro-Intestinal Syndrome

Development Status: NA

Corporate Partners: Memorial Sloan-Kettering Cancer Center

Funds Raised: NA

Presenter: Alton C. Morgan, PhD, President & CEO

Q Therapeutics, Inc.

Q Therapeutics develops neural cell therapeutics to treat diseases of the central nervous system. The company's first product is a cell-based therapeutic intended to restore or preserve normal activity of the neurons in the central nervous system. Its initial clinical target is ALS with its first IND submission expected in early 2015.

Location: Salt Lake City, Utah United States

Year Established: 2004

Website: www.qthera.com

Therapeutic Focus: Neurodegenerative Diseases

Development Status: IND submission targeted for early 2015; clinical trials in 2015

Corporate Partners: GBI, MPI Research

Funds Raised: \$26 M equity, including \$3.7 M by Cephalon (now Teva); \$4 M in NIH grant funding

Presenter: Deborah Eppstein, PhD, President & CEO

QBiotics Limited

This clinical-stage company is developing a clinical-stage NCE for the local treatment of a range of solid tumors in humans and companion animals. It is in Phase 1/2 for humans and Phase 2 for animal health. Its pipeline includes a wound-healing product.

Location: Indooroopilly, Queensland Australia

Year Established: 2004

Website: www.qbiotics.com

Therapeutic Focus: Oncology

Development Status: Human: Phase 1/2; Animal Health: Phase 2

Corporate Partners: Queensland Institute of Medical Research (QIMR); University of Queensland; IDT Australia; IDEXX; Iowa University Pharma; Intertek Cantox; USC; Ground Zero Pharma; INC Research (Clinical)

Funds Raised: \$40 M equity capital to date; QBiotics, \$21 M (818 shareholders); EcoBiotics (482 shareholders) owns 75+% of outstanding QBiotics shares.

Presenter: Dr. Victoria Gordon, Executive Director & CEO

Radius Health, Inc. (NASDAQ: RDUS)

Radius is a clinical-stage company developing new therapeutics for advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. Its lead candidate is nearing completion of a Phase 3 study to evaluate its ability to reduce fracture risks in postmenopausal women with osteoporosis.

Location: Waltham, Massachusetts United States

Year Established: 2003

Website: www.radiuspharm.com

Therapeutic Focus: Osteoporosis, Cancer, Endocrine-Mediated Diseases, Vasomotor Symptoms

Development Status: Phase 3

Corporate Partners: NA

Funds Raised: \$50 M IPO June 2014; raised \$53 M secondary, Aug. 2014; approx. \$150 M in private rounds

Presenter: Robert Ward, President & CEO

Relburn-Metabolomics, Inc.

This preclinical-stage company is developing drugs that treat gout by reducing the production and increasing the excretion of uric acid. This bifunctional activity has yielded clinical potency with a drug prototype. It is seeking financing to complete a pre-IND study.

Location: Westfield, New Jersey United States

Year Established: 2012

Website: www.relburn.com

Therapeutic Focus: Inflammation, Gout

Development Status: Phase 2 (with drug prototype); preclinical lead drug with IND filing projected in 2015

Corporate Partners: NA

Funds Raised: \$500,000

Presenter: Raymond P. Warrell, Jr., MD, Founder & CEO

Relmada Therapeutics, Inc. (OTCQB: RLMD)

Relmada Therapeutics is a clinical-stage specialty pharmaceutical company reformulating proven drugs as well as developing new chemical entities for the treatment of pain and diseases of the central nervous system.

Location: New York, New York United States

Year Established: 2004

Website: www.relmada.com

Therapeutic Focus: Pain, CNS

Development Status: Phase 2; Phase 1; Preclinical

Corporate Partners: NA

Funds Raised: \$50+ M to date, \$50+ M to date, including \$43 M in IPO 1H14 and warrant exercise in 2H14

Presenter: Sergio Traversa, PharmD, MBA, CEO

ReNeuron Group plc (LSE: RENE.L)

ReNeuron is a clinical-stage stem cell therapy company. Its primary therapeutic targets are stroke disability, critical limb ischemia and retinitis pigmentosa. Its lead candidate is in Phase 2 trials, and it is funded to pursue its clinical development program through the next two years.

Location: Guildford, Surrey United Kingdom

Year Established: 1998

Website: www.reneuron.com

Therapeutic Focus: CNS, Peripheral Vascular, Ophthalmology

Development Status: Phase 2 (lead)

Corporate Partners: NA

Funds Raised: Over \$100 M since IPO in 2005, incl. \$60 M in equity / grants, 2013

Presenter: Michael Hunt, CFO

RepliCel Life Sciences Inc. (TSX.V: RP)

RepliCel is a regenerative medicine company focused on developing autologous cell therapies that treat functional cellular deficits. In the next year it plans to have clinical trials under way for chronic Achilles tendinosis, damaged and aging skin, and hair loss.

Location: Vancouver, British Columbia Canada

Year Established: 2010

Website: www.replicel.com

Therapeutic Focus: Musculoskeletal, Dermatology, Pattern Hair Loss

Development Status: RCH-01: Phase 2, RCT-01: Phase 1/2, RCS-01: Phase 1

Corporate Partners: Shiseido Company, Limited; University of British Columbia, Department of Dermatology and Skin Science

Funds Raised: \$14 M with \$4 M in 2014, +\$755,000 from the exercise of warrants. \$4 M (Shiseido 2013)

Presenter: David Hall, CEO

RestorGenex Pharmaceuticals (OTCQB: RESX)

RestorGenex is a clinical-stage specialty biopharmaceutical company focused on the dermatology, ophthalmology and women's health markets. Its ophthalmology product targets age-related macular degeneration. Its dermatology business is focused on the treatment of keloid scarring, acne, unwanted excess hair and aging skin.

Location: Long Grove, Illinois United States

Year Established: 2013

Website: www.restorgenex.com

Therapeutic Focus: Dermatology, Ophthalmology, Women's Health, Oncology

Development Status: Phase 2, Phase 1

Corporate Partners: NA

Funds Raised: \$35.6 M raised in private placement in 2Q14

Presenter: Stephen M. Simes, CEO

Resverlogix Corp. (TSX: RVX)

Resverlogix is developing a small molecule selective BET bromodomain inhibitor for the treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease. It has completed Phase 2b trials.

Location: Calgary, Alberta Canada

Year Established: 2001

Website: www.resverlogix.com

Therapeutic Focus: Atherosclerosis, Cardiovascular Diseases, Diabetes Mellitus

Development Status: Phase 2b completed, Phase 2/3 in planning

Corporate Partners: NA

Funds Raised: \$230 M

Presenter: Donald J. McCaffrey, Co-Founder, President & CEO

RetroSense Therapeutics, LLC

RetroSense is a preclinical company developing gene therapeutics for vision restoration in retinitis pigmentosa and dry AMD. It anticipates filing an IND in early 2015.

Location: Ann Arbor, Michigan United States

Year Established: 2009

Website: www.retro-sense.com

Therapeutic Focus: Retinitis Pigmentosa, Dry Age-Related Macular Degeneration

Development Status: Finalizing IND enabling studies; anticipate IND filing 1Q15

Corporate Partners: NA

Funds Raised: Closed on \$5+ M in Series A

Presenter: Sean Ainsworth, Founder, Chairman & CEO

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN)

Rexahn Pharmaceuticals is a clinical-stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer. The company has three clinical-stage oncology candidates and a pipeline of preclinical compounds to treat multiple types of cancers.

Location: Rockville, Maryland United States

Year Established: 2001

Website: www.rexahn.com

Therapeutic Focus: Oncology

Development Status: Phase 2a, Phase 1b and Phase 1

Corporate Partners: NA

Funds Raised: \$110+ M with \$20+ M raised in 2014

Presenter: Peter D. Suzdak, PhD, CEO

RhinoCyte, Inc.

RhinoCyte is a preclinical-stage biotechnology company addressing the treatment of neurodegenerative disease using stem cell technology. It is preparing its lead product for Phase 1/2 trials.

Location: Louisville, Kentucky United States

Year Established: 2006

Website: rhinocyte.com

Therapeutic Focus: Spinal Cord injuries, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Type 1 Diabetes

Development Status: IND Submission/Preparation for Phase 1/2 Trials

Corporate Partners: Adjuvant Partners

Funds Raised: \$4+ M, public and private funding; \$5 M in investor financing

Presenter: Teresa Leezer, CEO

Rock Creek Pharmaceuticals (NASDAQ: RCPI)

Rock Creek is a preclinical life sciences company developing new drugs, formulations and compounds that provide therapies for inflammatory conditions, clinical immunology, neurological disease and behavioral health. Its lead molecule targets mechanisms of the cholinergic inflammatory pathways, inhibiting NF- κ B and the associated genetic cytokine cascade.

Location: Sarasota, Florida United States

Year Established: 1998

Website: www.rockcreekpharmaceuticals.com

Therapeutic Focus: Inflammation

Development Status: PreClinical/Clinical (Begin Phase 1 upon regulatory approval)

Corporate Partners: NA

Funds Raised: NA

Presenter: Michael J. Mullan, MBBS, Chairman & CEO

Rogne Bioscience, Inc.

Rogne is a preclinical company developing a topical biologic for the treatment of psoriasis. Its lead molecule is a non-steroidal topical with the efficiency of a biologic which demonstrates potent anti-inflammatory activity.

Location: Portola Valley, California United States

Year Established: 2011

Website: www.rognebioscience.com

Therapeutic Focus: Psoriasis, Inflammation

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: \$2 M

Presenter: Lena Wu, PhD, Co-Founder, President & CEO

RXi Pharmaceuticals Corp. (NASDAQ: RXII)

RXi Pharmaceuticals is a clinical-stage biotechnology company that discovers, develops and commercializes therapies based on its self-delivering RNAi platform. Its first product candidate is currently being evaluated in Phase 2 clinical trials to reduce the formation of dermal scars.

Location: Marlborough, Massachusetts United States

Year Established: 2011

Website: www.rxipharma.com

Therapeutic Focus: Dermatology, Ophthalmology, Fibrotic Conditions

Development Status: Phase 2a

Corporate Partners: NA

Funds Raised: NA

Presenter: Geert Cauwenbergh, Dr. Med. Sc., President & CEO

Savara Pharmaceuticals

Savara is a clinical-stage specialty pharmaceutical company developing drugs for the treatment of serious and life-threatening conditions. Its lead product in development is a dry powder inhaled antibiotic for the treatment of MRSA in patients with cystic fibrosis.

Location: Austin, Texas United States

Year Established: 1997

Website: www.savarapharma.com

Therapeutic Focus: Anti-infective, Cystic Fibrosis, Inhalation

Development Status: Phase 2a

Corporate Partners: NA

Funds Raised: \$29 M

Presenter: Rob Neville, CEO

Scholar Rock, Inc.

Scholar Rock is a preclinical-stage company discovering biologic therapies that selectively modulate the activation of growth factors in the disease microenvironment. Its current programs target members of the TGF-beta superfamily, which are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal system and autoimmune diseases.

Location: Cambridge, Massachusetts United States

Year Established: 2013

Website: www.scholarrock.com

Therapeutic Focus: Fibrosis, Musculoskeletal Diseases, Autoimmunity

Development Status: Discovery and preclinical-stages

Corporate Partners: Janssen Biotech/Johnson & Johnson Innovation

Funds Raised: \$20+ M as of Sept. 2014

Presenter: Nagesh K. Mahanthappa, PhD, MBA, President & CEO

Sequentia, Inc.

Sequentia uses a platform technology to develop clinical diagnostics to help decode the body's immune response that has applications across medical conditions and in drug development. The company's first commercialized product is a test for MRS in blood cancer patients.

Location: South San Francisco, California United States

Year Established: 2008

Website: www.sequentia.com

Therapeutic Focus: Immune Response, Immunotherapy, Autoimmune Disease, Hematological Oncology

Development Status: Marketed

Corporate Partners: NA

Funds Raised: \$40 M in venture funding through Series C; undisclosed \$ from strategic partners, including Celgene Corp. in Series D

Presenter: Tom Willis, PhD, Co-Founder & CEO

SolaranRx, Inc.

This early-stage company is developing radiopharmaceutical therapies and companion imaging agents to treat metastatic melanoma. It is seeking funding to take its lead product through proof-of-concept studies.

Location: Albuquerque, New Mexico United States

Year Established: 2014

Website: solaranrx.com

Therapeutic Focus: Oncology

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: \$120,000 from founders

Presenter: Les Stewart, Co-Founder, President & CEO

Sorrento Therapeutics, Inc. (NASDAQ: SRNE)

Sorrento is developing treatments for cancer and associated pain. Its next-generation paclitaxel started its registrational trial in March 2014. It also has a non-opiate TRPV1 agonist in a Phase 1/2 study at the NIH to treat terminal cancer patients for pain.

Location: San Diego, California United States

Year Established: 2006

Website: sorrentotherapeutics.com

Therapeutic Focus: Oncology, Cancer Pain

Development Status: Cynviloq Phase 3, RTX Phase 1/2

Corporate Partners: Morphotek, Scripps Clinic

Funds Raised: \$79.9 M raised through issuance of common stock, net

Presenter: Henry Ji, CEO

Starpharma Pty. Ltd. (ASX: SPL)

This platform company has a portfolio of products based on its polymers technology. Its drug delivery platform includes a clinical-stage oncology candidate. Its antimicrobial is in Phase 3 trials for the management of bacterial vaginosis and is marketed as the first antiviral condom.

Location: Melbourne, VIC Australia

Year Established: 2000

Website: www.starpharma.com

Therapeutic Focus: Drug Delivery, Oncology, Women's Health

Development Status: Marketed (VivaGel Condom), Regulatory & Phase 3 (VivaGel), Phase 1 DEP docetaxel (Oncology)

Corporate Partners: Astra Zeneca, Lilly, GSK, and undisclosed top 10 Pharmas

Funds Raised: AUD \$80+ M to date

Presenter: Jackie Fairley, BSc, BVSc (Hons), MBA, CEO

Stellar Biotechnologies, Inc. (OTCQX: SBOTF)

Stellar Biotechnologies is a development-stage company that sustainably manufactures KHL, an immune-stimulating protein used in therapeutic and diagnostic markets. It is also an active pharmaceutical ingredient in many immunotherapies that target cancer, immune disorders, Alzheimer's and inflammatory diseases.

Location: Port Hueneme, California United States

Year Established: 1999

Website: www.stellarbiotech.com

Therapeutic Focus: Active Immunotherapy

Development Status: Development Stage

Corporate Partners: Neovacs, S.A., Araclon Biotech, S.L., Amaran Biotechnology, Inc, OBI Pharma, Biovest International, Inc.

Funds Raised: \$25+ M in equity and \$7 M in grants

Presenter: Frank R. Oakes, Chairman, President & CEO

StemBioSys Inc.

StemBioSys is a development-stage biomedical company focused on the isolation, expansion and delivery of specialized adult stem cells for research, diagnostic and clinical use. Its first product for bone healing is in final development of the research market and in preclinical study for therapeutic applications.

Location: San Antonio, Texas United States

Year Established: 2010

Website: www.stembiosys.com

Therapeutic Focus: Research Products Market, Bone Healing

Development Status: Final product development for Research market; Preclinical for therapeutic application

Corporate Partners: NA

Funds Raised: Approx. \$6.9 M to date, \$6.25 M in Series A offering; remainder from founders

Presenter: Robert Hutchens, President & CEO

Stemedica International SA

Stemedica is a biotechnology company that develops therapeutic applications for the treatment and prevention of Alzheimer's disease based on its stem cell technology. It has products in various stages of clinical development.

Location: Epalinges, Switzerland

Year Established: 2008

Website: stemedica-intl.com

Therapeutic Focus: Alzheimer's

Development Status: Preclinical, Phase 2a anticipated 2Q15

Corporate Partners: Thermo Fisher/Life Technologies

Funds Raised: \$5 M, 2014; Stemedica Cell Technologies (parent co.) \$90+ M since 2005

Presenter: David Cheatham, MBA, Business Manager

Synthetic Biologics, Inc. (NYSE MKT: SYN)

Synthetic Biologics is a clinical-stage company developing pathogen-specific therapies with a focus on the microbiome to protect the GI microflora from the effects of IV antibiotics in order to prevent *C. difficile* infection, reduce the impact of methane-producing organisms on C-IBS, treat pertussis and treat relapsing-remitting MS.

Location: Rockville, Maryland United States

Year Established: 2001

Website: www.syntheticbiologics.com

Therapeutic Focus: Microbiome; Infectious Diseases; Central Nervous System

Development Status: Trimesta: Phase 2; SYN-004: Phase 1a; SYN-010: Phase 2 (1H 2015); SYN-005: Preclinical

Corporate Partners: Intrexon Corp.; University of Texas (Austin); Cedars-Sinai Medical Center; The Regents of University of California

Funds Raised: ~\$74 M to date

Presenter: Jeffrey Riley, CEO

Theranostics Health, Inc.

This revenue-generating company is a provider of proteomic-based molecular diagnostic assays for oncologists that measure signaling activity across a panel of drug targets in each unique tumor. Its marketed product is used in breast cancer, and it plans to expand into colorectal and lung cancers in 2015.

Location: Rockville, Maryland United States

Year Established: 2007

Website: www.theranosticshealth.com

Therapeutic Focus: Oncology

Development Status: Early Commercial

Corporate Partners: med fusion, www.medfusionservices.com

Funds Raised: \$10 M in private equity plus \$12 M in pharma services revenues

Presenter: Luis T. Gutierrez, Jr., President & CEO

Therapix Biosciences Ltd. (TASE: TRPX)

Therapix is a preclinical specialty pharmaceutical company that is focusing on the microbiome to protect the GI microflora from the effects of IV antibiotics to prevent or treat infectious diseases such as *C. difficile* infection as well as diseases of the central nervous system including MS.

Location: Tel Aviv, Israel

Year Established: 2004

Website: www.therapixbio.com

Therapeutic Focus: Pain, MS Spasticity, CINV, Anti-inflammatory

Development Status: Preclinical; plans to pursue approvals via 505(B)(2)

Corporate Partners: NA

Funds Raised: Approx. \$3.5 M through private placements in 2013 and 2014

Presenter: Jan Turek, CEO

Thermalin Diabetes, LLC

Thermalin is a preclinical-stage diabetes company with new delivery technologies including never-needs-refrigeration insulins and rapid-acting insulins. Its lead product is entering Phase 1 trials.

Location: Waban, Massachusetts United States

Year Established: 2009

Website: www.thermalin.com

Therapeutic Focus: Diabetes

Development Status: Entering Phase 1a on lead program

Corporate Partners: JDRF

Funds Raised: \$11.5 M in investment plus \$9.5 M in grants

Presenter: Richard Berenson, CEO

TiGenix NV (EURONEXT: TIG)

TiGenix is a late clinical-stage company developing and commercializing therapeutics from its platform of allogeneic expanding adipose-derived stem cells in inflammatory and autoimmune diseases. It has one marketed product and others in various stages of clinical development.

Location: Leuven, Belgium

Year Established: 2000

Website: www.tigenix.com

Therapeutic Focus: Autoimmune

Development Status: Pipeline products in Phase 3, Phase 2 and Phase 1, and one marketed product

Corporate Partners: Swedish Orphan Biovitrum AB ('Sobi')

Funds Raised: NA

Presenter: Eduardo Bravo, CEO

Tolero Pharmaceuticals, Inc.

Tolero develops therapeutics for life-threatening diseases. Its pipeline includes one product for myeloid leukemia in Phase 2 and several others in preclinical development including two that will enter the clinic in early 2015. The company is currently focused on lung, prostate and pancreatic cancers, B-cell malignancies and multiple myeloma.

Location: Lehi, Utah United States

Year Established: 2011

Website: www.toleropharma.com

Therapeutic Focus: Oncology, Hematology

Development Status: Alvocidib: Phase 2, preparing for Phase 3. All others preclinical, two of which will be in the clinic early 2015

Corporate Partners: Sanofi; MannKind

Funds Raised: \$3.3 M Series A round, 2013; \$22.9 M Series B round Oct. 2014

Presenter: Michael McCullar, PhD, MBA, COO

TomegaVax, Inc.

This preclinical company develops therapeutic and prophylactic vaccines for infectious diseases using a platform that delivers a long-term T helper cell response. It has achieved proof of concept in SIV, TB and malaria in monkeys.

Location: Beaverton, Oregon United States

Year Established: 2011

Website: www.tomegavax.com

Therapeutic Focus: Infectious Diseases

Development Status: Preclinical development

Corporate Partners: One big pharma research partnership, confidential

Funds Raised: \$100 M in grants/ foundation funding (past 10 yrs); \$6.5 M grants (2014); \$25 M from Gates Foundation.

Presenter: Michael Tippie, CEO

Trovagene, Inc. (NASDAQ: TROV)

The company uses technology that detects and monitors cell-free DNA in urine to quantitate oncogene mutations in cancer patients to improve disease management. Its cancer monitoring platform is designed to provide clinical information that is beyond the current standard of care and is protected by significant intellectual property.

Location: San Diego, California United States

Year Established: 1999

Website: www.trovagene.com

Therapeutic Focus: Oncology Care Management

Development Status: NA

Corporate Partners: NA

Funds Raised: \$83 M

Presenter: Antonius Schuh, PhD, CEO

Valley Fever Solutions, Inc.

Valley Fever Solutions will begin Phase 2a trials for its lead product in 2015 moving toward approval against valley fever as a first indication. The product is part of a new class of antifungals which the company believes will demonstrate efficacy against other fungi.

Location: Tucson, Arizona United States

Year Established: 2007

Website: www.ValleyFeverSolutions.com

Therapeutic Focus: Valley Fever (Coccidioidomycosis)

Development Status: Phase 2a

Corporate Partners: NA

Funds Raised: \$10 M in grants bringing project to two planned trials funded by the NIH. Add'l \$1.7 M grant for one of those trials.

Presenter: David Larwood, President & CEO

Vaxart Inc.

Vaxart is an early clinical-stage company developing a range of vaccines that are administered by tablet. In Phase 1 studies its seasonal flu tablet vaccine generated broad immune responses in 92% of subjects. Ebola and norovirus vaccine candidates are expected to enter the clinic in 2015.

Location: South San Francisco, California United States

Year Established: 2004

Website: www.vaxart.com

Therapeutic Focus: Vaccines

Development Status: Phase 1 for Viral Infections. (Influenza, Ebola, Norovirus)

Corporate Partners: NA

Funds Raised: \$39.2 M as of Oct. 13, 2014

Presenter: Wouter Latour, MD, MBA, CEO

Venaxis® , Inc. (NASDAQ: APPY)

Venaxis® is an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid blood-based test designed to aid emergency room clinicians in identifying children, adolescent, and young adult patients who are at low risk for appendicitis.

Location: Castle Rock, Colorado United States

Year Established: 2000

Website: www.venaxis.com

Therapeutic Focus: Acute Abdominal Pain

Development Status: CE Marked, Under FDA Review

Corporate Partners: NA

Funds Raised: NA

Presenter: Steve Lundy, President & CEO

Verona Pharma Plc (LSE: VRP)

Verona Pharma is a clinical-stage biopharmaceutical company developing medicines to treat respiratory diseases such as COPD, asthma and cystic fibrosis. Its lead drug is currently in Phase 2 trials as a nebulized treatment for acute exacerbations of COPD in a hospital setting.

Location: London, United Kingdom

Year Established: 2005

Website: www.veronapharma.com

Therapeutic Focus: Respiratory Diseases

Development Status: Phase 2

Corporate Partners: NA

Funds Raised: £14 M in March 2014, and has raised £29 M since inception

Presenter: Dr. Jan-Anders Karlsson, CEO

ViaCyte, Inc.

ViaCyte is a clinical-stage regenerative medicine company developing a cell therapy for the treatment of diabetes. The company has reviewed its lead product with the regulatory authorities at the FDA and Health Canada. It initiated FIH clinical trials in patients with Type 1 diabetes in 2014.

Location: San Diego, California United States

Year Established: 1999

Website: www.viacyte.com

Therapeutic Focus: Diabetes

Development Status: Clinical Phase 1/2; FIH in 2014

Corporate Partners: California Institute for Regenerative Medicine; JDRF; Nestle Institute of Health Sciences; JJDC; Sanderling Ventures; Asset Management Company

Funds Raised: \$69+ M from CIRM and JDRF combined; \$93 M since inception

Presenter: Paul Laikind, PhD, President & CEO

ViroCyt, LLC

ViroCyt is a commercial-stage company with a flow cytometry platform that can count extremely small biologic particles in real time. Its current product is applicable to numerous viruses and virus-like particles. It is developing new affinity reagents that will provide target specificity when used with the small particle counter instrument.

Location: Boulder, Colorado United States

Year Established: 2012

Website: www.virocyt.com

Therapeutic Focus: Virus quantification; Bacteria, Yeast, Liposomes, Exosomes

Development Status: Commercial

Corporate Partners: Existing customers include Amgen, Biogen IDEC, Crucell, FDA, Genentech, Merck, NIH, OHSU, Sanofi Pasteur and USAMRID

Funds Raised: \$4.7 M Series A in 2012

Presenter: Robert Kline, President & CEO

ViroMed Co., Ltd. (KOSDAQ: 84990)

ViroMed is a clinical-stage biotechnology company with two areas of focus, DNA/protein-based biopharmaceuticals and phytotherapeutics. It has five main products in its pipeline targeting cardiovascular disease, cancer and immune-related disorders with clinical trials under way in the US, Korea and China.

Location: Seoul, Republic of Korea

Year Established: 1996

Website: www.viromed21.com

Therapeutic Focus: Cardiovascular, Neurology, Oncology, Pain, Nutraceutical, Botanical Medicine,

Development Status: Phase 2

Corporate Partners: Beijing Northland Biotech Co., Ltd. (China); Reyon Pharmaceutical Co., Ltd. (Korea)

Funds Raised: \$50 M

Presenter: Sunyoung Kim, PhD, Founder & CSO

Viscogel AB

Viscogel is a clinical-stage company that is developing a versatile hydrogel that is currently being tested by major US and Japanese pharmaceutical companies for the delivery of small molecules, biologics and viruses. It also has an in-house program for oncological and ophthalmological drug development.

Location: Solna, Sweden

Year Established: 2007

Website: www.viscogel.se

Therapeutic Focus: Drug Delivery, Oncology

Development Status: Phase 1/2

Corporate Partners: Major US-Pharma/Biotechs and Major Japanese Pharmas

Funds Raised: Approx. \$10 M through angels

Presenter: Ulf Ljungberg, CEO

VisionGate, Inc.

VisionGate is an in vitro diagnostics company that is nearing commercialization of its technology that generates hi-resolution 3-D images from intact cells for early disease detection. It is already marketing a non-invasive diagnostic test for early lung cancer detection.

Location: Phoenix, Arizona United States

Year Established: 2001

Website: www.visiongate3d.com

Therapeutic Focus: Oncology

Development Status: CLIA lab - LDT

Corporate Partners: Fred Hutchinson Cancer Center, Sheba Medical School (Israel); Baptist Hospital, Swedish Cancer Center, University of Toronto, and University of Navarra (Spain)

Funds Raised: \$20 M to date plus \$4 M in grants

Presenter: Alan Nelson, PhD, Founder, Chairman & CEO

VolitionRx Limited (OTCQB: VNRX)

This clinical-stage company is developing blood-based cancer diagnostic tests for colorectal cancer and other diseases.

Location: Namur, Belgium

Year Established: 2010

Website: www.volitionrx.com

Therapeutic Focus: Cancer Diagnostics

Development Status: Clinical trials under way for NuQ colorectal cancer test

Corporate Partners: NA

Funds Raised: ~ USD \$14 M in equity capital; ~ €2 M (Belgian Gov't. grants)

Presenter: Cameron Reynolds, CEO

Vyrix Pharmaceuticals, Inc.

Vyrix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on urology and male sexual dysfunction. The company's lead product for premature ejaculation is Phase 3-ready and has already undergone two European Phase 3 trials.

Location: Englewood, Colorado United States

Year Established: 2013

Website: www.vyrixpharma.com

Therapeutic Focus: Urology, Male Sexual Dysfunction

Development Status: Phase 3

Corporate Partners: The company is a subsidiary of Ampio Pharmaceuticals

Funds Raised: Internally funded by Ampio Pharmaceuticals; pursuing add'l funding

Presenter: Jarrett Disbrow, President & CEO

Wasatch Microfluidics, LLC

This commercial-stage company markets a microfluidic technology for biomolecular binding analysis in drug discovery. It expects to release its next generation product within 16 months.

Location: Salt Lake City, Utah United States

Year Established: 2005

Website: www.microfl.com

Therapeutic Focus: Tools

Development Status: Initial product generating revenue; next product release 2016.

Corporate Partners: Pfizer

Funds Raised: \$1 M (Pfizer seed funding); \$3.3 M equity capital (multiple angels); \$4 M from NIH, NSF & State of Utah non-dilutive funding

Presenter: Josh Eckman, President & CEO

WEX Pharmaceuticals Inc.

This clinical-stage company has a Phase 3 non-opioid small molecule technology. It is preparing an NDS for cancer-related pain in Canada and a second program for Phase 2 in the US for chemotherapy-induced neuropathic pain.

Location: Vancouver, British Columbia Canada

Year Established: 1987

Website: www.wexpharma.com

Therapeutic Focus: Neurology, Pain

Development Status: Regulatory submission for NDS in Canada, Phase 2 in US

Corporate Partners: Subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (CKLS), a member of the Cheung Kong Group

Funds Raised: A subsidiary of CK Life Sciences

Presenter: Walter Korz, VP & General Manager

WILEX AG (FRANKFURT: WL6)

WILEX is a clinical-stage company with diagnostic and therapeutic product candidates for various types of cancer. Through a subsidiary it also offers an antibody drug conjugate technology platform. Its lead product is in Phase 3a clinical trials.

Location: Munchen, Bayern Germany

Year Established: 1997

Website: www.wilex.com

Therapeutic Focus: Oncology, ADC Technology,

Development Status: Phase 3a, Phase 2a, ADC Technology platform

Corporate Partners: Roche, RedHill Pharmaceuticals, Link Health, F-Star

Funds Raised: More than €100 M, including €16 M in 2012

Presenter: Jan Schmidt-Brand, PhD, CEO & CFO

Xcovery

Xcovery Holding Company is a clinical-stage company developing a broad portfolio of small molecule targeted therapeutics for cancer and ophthalmology. It has a pipeline of oncology therapies that target a wide range of advanced tumors as well as an oral treatment for wet age-related macular degeneration that could replace the need for monthly injections.

Location: West Palm Beach, Florida United States

Year Established: 2006

Website: www.xcovery.com

Therapeutic Focus: Oncology, Ophthalmology

Development Status: Phase 2, Phase 3

Corporate Partners: NA

Funds Raised: NA

Presenter: Michael Webb, President & CEO

XEME Biopharma Inc.

XEME is a clinical-stage company in Phase 1/2 trials of personalized therapeutic cancer vaccines for hematologic malignancies. It also has a pipeline of Phase 1/2 ready projects for solid tumors including off-the-shelf candidates.

Location: Monmouth Junction, New Jersey United States

Year Established: 2005

Website: www.xemebiopharma.com

Therapeutic Focus: Oncology

Development Status: Clinical-stage, First in Man (Phase 1 B) and Phase 2 (Pilot)

Corporate Partners: Cancer Treatment Centers of America; Oncothyreon.

Funds Raised: Angel investors, SBIR grants & founder contributions. Acquired by TheraTest Labs in Dec. 2011, which has invested \$5 M

Presenter: Larry Kwak, MD, PhD, Founder & Chairman SAB

Zocere Inc.

Zocere is a preclinical company with a drug candidate that is a cell-permeable, recombinant peptide that crosses the blood-brain barrier, is resistant to degradation and has been shown to reduce brain damage in animal models of stroke.

Location: Albuquerque, New Mexico United States

Year Established: 2013

Website: www.zocere.com

Therapeutic Focus: Stroke (Neurovascular)

Development Status: Preclinical

Corporate Partners: NA

Funds Raised: \$500,000 from New Mexico Angels and a private equity fund

Presenter: Wayne Laslie, President & CEO

NOTE:

The information contained in this book is current as of December 24, 2014 and was obtained through sources believed to be reliable, including information provided by the company and company websites. Information was edited to fit into the format of this book.

Demy-Colton Life Science Advisors and EBD Group, the organizers of Biotech Showcase, do not guarantee that this information is complete or correct nor do they warrant the information for a particular purpose. The organizers do not underwrite securities or make markets in them. The presenting companies may participate in other meetings produced by the organizers.

NOTES

BIOTECH SHOWCASE™ 2015

BIOTECH SHOWCASE IS PRODUCED BY
DEMY COLTON LIFE SCIENCE ADVISORS
AND EBD GROUP.

BOTH ORGANIZATIONS HAVE
A LONG HISTORY OF PRODUCING
HIGH-QUALITY PROGRAMS
THAT SUPPORT THE
BIOTECHNOLOGY AND
BROADER LIFE SCIENCES INDUSTRIES.

**DEMY
COLTON**

**EBD
GROUP**